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ABSTRACT
HUMAN HEPATOCELLULAR CARCINOMA CELLS ADAPT TO ASCT2
AND LAT1 AMINO ACID TRANSPORTER KNOCKDOWN
MEDIATED BY SHRNA AND CRISPR-CAS9
Paige Bothwell, Ph.D.
Department of Biological Sciences
Northern Illinois University, 2017
Dr. Barrie Bode, Director
Amino acid transporters ASCT2 and LAT1 are coordinately enhanced in human cancers
where, among other roles, they are thought to drive mammalian target-of-rapamycin (mTOR)
growth signaling. To assess the value of ASCT2 and LAT1 as therapeutic targets in
hepatocellular carcinoma (HCC), nine unique shRNA sequences in lentiviral vectors were used
to produce sTable transporter suppression in epithelial and mesenchymal HCC cell lines. In
addition, direct genomic editing of the ASCT2 and LAT1 genes (SLC1A5 and SLC7A5,
respectively) was performed using six unique CRISPR-Cas9 vectors. Both targeting systems
were successful, and glutamine and leucine uptake rates were reduced proportionally to
diminished transporter protein expression in each cell line. A greater degree of knockout was
achieved by the CRISPR-Cas9 gene editing system versus the sTable shRNA expression system
(75-90% versus 20-80% respectively). Contrary to expectations, diminished glutamine and
leucine influx failed to substantially affect cellular proliferation. Analysis of mTOR complex 1
(mTORC1) signaling output showed no compromise to basal or amino acid-stimulated signaling
to growth and autophagy, as assessed by the phosphorylation of three targets: eukaryotic
translation initiation factor 4E binding protein 1 (4E-BP1), ribosomal protein S6 kinase beta-1
(p70S6K), and Unc-51 like autophagy activating kinase 1 (ULK1). In addition, quantitative RTPCR indicated no significant upregulation of other amino acid transporters or glutamine
synthetase (GLUL) to supplement the intracellular availability of glutamine. Western blot

analysis revealed an increased expression of glucose transporter 1 (GLUT1) expression in
response to ASCT2 knockout, a response that was unique to mesenchymal type HCC.
Subsequent evaluation of prolonged uptake of radiolabeled glutamine and leucine demonstrated
that diminished transport rates do not affect the total intracellular accumulation of either amino
acid in ASCT2 and LAT1 transporter knockout cell lines. Further in vivo analysis will be
essential to understanding the noTable upregulation of ASCT2 and LAT1 across cancers, and
these findings do not exclude the possibility that these transporters play a role in tumorigenesis
and metastasis. The results presented herein establish that, in an in vitro context, HCC cell lines
are able to adapt to decreased rates of amino acid transport.
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INTRODUCTION

A Focus on Cancer Metabolism

Cancerous transformation of cells and the subsequent stages of tumorigenesis involve a
metabolic and physiological re-programming to support constitutive growth. Such derangements
involve enhanced glucose uptake and glycolytic metabolism (“the Warburg effect”), as well as
accelerated glutamine transport and glutaminolysis (DeBerardinis, Lum, Hatzivassiliou, and
Thompson, 2008; Iaccarino and Martins, 2011; Warburg, 1956). While these physiological
aspects of cancer have been recognized for decades, there is currently a renewed interest in their
molecular underpinnings in the hope of finding therapeutic strategies that are more acutely
targeted. If modern research can identify specific vulnerabilities in cancer biology and design
therapies tailored to distinctive patient populations, then the next generation of treatment options
will be more effective and conscientious of detrimental effects on healthy tissue. Cancer is not a
single disease. There is significant variation amongst different cancers, nuanced by the type of
tissue giving rise to a primary tumor, the stage of progression, as well as metabolic profile,
heterogeneity, and plasticity across the cells that comprise a tumor. Cellular metabolism within a
tumor is dynamic and subject to changing nutrient conditions in the tumor microenvironment,
and the formation of metabolic networks between tumor and stomal cells may also play a
significant role in tumor sustenance and survival (Romero, Mukherjee, Kenny, Litchfield, and
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Lengyel, 2015). The multifaceted nature of cancerous transformation and survival requires
investigative approaches that are capable of differentiating between gene targets that are essential
to growth or impart an adaptive capacity and those targets that may only be accessory to more
important cellular survival programs and therefore are ineffectual in therapeutic applications.
Fortunately, the advancement of genome and transcriptome sequencing tools have led to
the creation of vastly informative databases such as the Cancer Genome Anatomy Project
(CGAP), the Cancer Genome Atlas (TCGA), and the Cancer Gene Expression Database
(CGED), amongst others, and these assemblies have been critical to the selection of potential
therapeutic targets in tumor metabolism (Kato et al., 2005; Krizman, Wagner, Lash, Strausberg,
and Emmert-Buck, 1999; Tomczak, Czerwinska, and Wiznerowicz, 2015; Wishart, Mandal,
Stanislaus, and Ramirez-Gaona, 2016). In part of the foundational work which set the stage for
this project, Dr. Brian Fuchs and Dr. Barrie Bode used the human expressed sequence tag (EST)
database from the CGAP to identify a pronounced and coordinately enhanced expression of two
amino acid transporters, alanine-serine-cysteine transporter 2 (ASCT2) and large neutral amino
acid transporter 1 (LAT1), across a variety of human cancers, including cancers of the brain,
colon, eye, kidney, liver, lung, lymph node, muscle, ovary, skin, placenta, and stomach, relative
to normal tissue (Fuchs and Bode, 2005). These two transporters were therefore selected for a
comprehensive investigation into their importance to cancer survival and their potential as
specific targets in therapeutic development.
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ASCT2 and LAT1 Amino Acid Transporters

The ASCT2 and LAT1 amino acid transporters function in a cooperative, tertiary
antiporter mechanism (Figure 1). ASCT2 (in blue) is broad specificity Na+-dependent antiporter
which exploits the electrochemical gradient of sodium across the plasma membrane to exchange
one small, neutral amino acid from the cytoplasmic side for one small, neutral amino acid and a
sodium ion on the extracellular side. LAT1 (in red) also functions as an antiporter, but its
function is Na+-independent. LAT1 forms a disulfide-linked heterodimeric protein complex in
the plasma membrane with the glycosylated heavy subunit 4F2 heavy chain (4F2hc/CD98) (in
lavender). LAT1 utilizes the intracellular pool of amino acids generated by ASCT2 activity to
exchange one small, neutral amino acid from the intracellular side for one large, essential amino
acid from the extracellular side (Fuchs and Bode, 2005). Together, the activity of these two
transporters effectively generates a pool of essential amino acids that stimulates the activity of
mammalian target-of-rapamycin complex 1 (mTORC1), a serine threonine kinase which, as will
be discussed later, is critical activator of cap-dependent protein translation and also acts to inhibit
autophagy (Fuchs, Finger, Onan, and Bode, 2007; Nicklin et al., 2009).
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Figure 1. ASCT2 and LAT1 transport mechanism. ASCT2 and LAT1 mediate a bidirectional
transport of amino acids. The coorperative function of these transporters produces an intracellular
pool of essential amino acids which stimulates mammalian target-of-rapamycin complex 1
(mTORC1) downstream. Image created in reference to Fuchs & Bode, 2005.

The gene encoding ASCT2 (SLC1A5) has been identified as a direct target of the c-Myc
transcription factor in mouse embryonic fibroblast cells (MEFs), and the gene encoding LAT1
(SLC7A5) has been identified as a target of c-Myc and n-Myc in MIA Paca-2 human pancreatic
carcinoma and KELLY human neuroblastoma cells respectively (Brown et al., 1995; Brunn et
al., 1997; Hayashi, Jutabha, Endou, and Anzai, 2012; Jung et al., 2009; Qing et al., 2012; L.
Wang et al., 2007; Wise et al., 2008). Therefore, the ASCT2 and LAT1 transporters are thought
to be participants in a Myc-driven transcriptional program that stimulates mitochondrial
glutamine metabolism and glycolytic diversion in many cancers (Fuchs and Bode, 2005; Wise
and Thompson, 2010). Briefly, glutamine imported into the cell by the activity of ASCT2 may be
used as a substrate for energy production in the tricarboxylic acid (TCA) cycle by entering at the
level of α-ketoglutarate (DeBerardinis et al., 2008). This can only occur after glutamine is first
deaminated to form glutamate by mitochondrial glutaminases and then converted to αketoglutarate by either glutamate dehydrogenase or aminotransferase enzymes. The consumption
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of glutamine by the TCA cycle is driven by a modified oxidative phosphorylation pathway in
cancer, and many of the aberrant genetic changes responsible for this shift in metabolism have
been reviewed (Fendt et al., 2013; Sullivan, Gui, and Vander Heiden, 2016). The enhanced
influx of glutamine into the TCA cycle is concurrent to a diminished entry of pyruvate upstream
due to another hallmark of cancer metabolism, aerobic glycolysis, also known as “the Warburg
effect.” Instead of entering the TCA cycle, pyruvate generated from enhanced glycolytic activity
is converted to lactate, regardless of oxygen availability (Warburg, 1956). Several competing
explanations exist for the purpose of a glycolytic/glutaminolytic shift in cancer, but no clear
consensus has been reached to this date (Liberti and Locasale, 2016).
Intermediates of these catabolic pathways, glycolysis and the TCA cycle, may also be
selectively diverted into alternative anabolic pathways, such as nucleotide and lipid biosynthesis.
By sustaining the cellular import of glutamine, the ASCT2 transporter may also invigorate
pathways involving redox homeostasis through glutathione biosynthesis, protein translation, and
hexosamine biosynthesis which contributes to N-linked and O-linked glycosylation reactions that
produce protein and lipid modifications in cellular signal transduction and secretion pathways
(Alberghina and Gaglio, 2014; Anastasiou and Cantley, 2012; Kaadige, Looper, Kamalanaadhan,
and Ayer, 2009; Tong, Zhao, and Thompson, 2009; Wellen et al., 2010). Despite the
upregulation of ASCT2 and LAT1 across a broad spectrum of cancers and their potential to
functionally contribute to a variety of unique cancerous metabolic demands, these two
observations cannot be naturally connected without pause for consideration. ASCT2 and LAT1
may upregulated because they impart competitive edge by supporting intracellular amino acid
availability. However, their upregulation may also be a byproduct of a shared stimulatory
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pathway or promoter homology to another more critical molecular player that is subject to
selection in cancerous transformation and survival.

ASCT2 and LAT1 in Human Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is a particularly recalcitrant cancer with few treatment
options, and the incidence of HCC in the United States is increasing, largely due to chronic
hepatitis C virus infection (de Oliveria Andrade et al., 2009). As a major regulatory center for
both glucose and amino acid metabolism, the liver provides both challenges and opportunities for
physiological therapeutic intervention in HCC. In normal human hepatocytes, ASCT2 and LAT1
expression levels are low, but both transporters are enhanced in hepatoma cells, making them
compelling and potentially discriminating therapeutic targets for HCC. ASCT2 has an
appreciable initial-rate glutamine uptake in HCC cells, with a higher affinity for glutamine than
System N transporters (SLC38A3,5/SNAT3,5) by 10- to 30-fold (Bode, Kaminski, Souba, and Li,
1995). The activity of ASCT2 has been shown to dominate glutamine transport in human HCC
cells, whereas the System N transporters (SLC38A3,5/SNAT3,5) mediate the majority of
glutamine uptake in healthy human hepatocytes (Bode et al., 2002).
In previous work, ASCT2 was targeted for suppression by the implementation of a stably
maintained mifepristone-inducible dual vector system which encoded an ASCT2-specific
antisense RNA. Upon induction, antisense RNA expression correlated strongly to reduced
expression of the ASCT2 protein and the rapid onset of an apoptotic response in human HCC
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cells (Fuchs et al., 2004), a process that involves early inhibition of mTORC1-mediated growth
signaling (Fuchs et al., 2007). Subsequent work confirmed that ASCT2 and LAT1 indeed
synergize to drive mTORC1 signaling and suppress autophagy in HeLa cells (Nicklin et al.,
2009). Overall, amplified mTORC1 signaling is now a well-characterized major driver of HCC
growth (Ashworth and Wu, 2014). This work has collectively contributed to the current model of
ASCT2 and LAT1 participation in mTORC1-mediated growth signaling (Figure 2). Two major
signals are responsible for the activation of mTORC1 growth signaling: (1) the accumulation of
intracellular essential amino acids resulting from cooperative ASCT2 and LAT1 transport
activity as well as the activity of the ubiquitin-mediated 26S proteasome (Fuchs and Bode, 2005;
Wu et al., 2009) and (2) the phosphorylation activity of protein kinase B (PKB/Akt) resulting
from growth factor stimulation of tyrosine kinase receptors (Inoki, Li, Zhu, Wu, and Guan, 2002;
Inoki, Zhu, and Guan, 2003; Wullschleger, Loewith, and Hall, 2006; Nascimento et al., 2010).
Active mTORC1, a serine threonine kinase, is capable of phosphorylating a variety of
intracellular targets illustrated in preceding Figure 2 (Brown et al., 1995; Brunn et al., 1997;
Hosokawa et al., 2009; Jung et al., 2009; Kim, Kundu, Viollet, and Guan, 2011; Redpath,
Foulstone, and Proud, 1996; L. Wang, Harris, Roth, and Lawrence, 2007), and collectively, the
phosphorylation of these targets promotes the activation of cap-dependent translation (3) and the
suppression of autophagy (4). Conversely, when the intracellular ratio ATP:AMP is low,
adenosine monophosphate-activated protein kinase (AMPK) will phosphorylate the Raptor
subunit of mTORC1, the TSC1/2 complex, and the Unc-51 like autophagy activating kinase 1/2
(ULK1/2) complex, among other targets, and thus, AMPK is able to reverse the actions of
mTORC1 when energy levels are low (Mihaylova and Shaw, 2011).
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Figure 2. Illustration of mammalian target-of-rapamycin complex 1 (mTORC1) activation and activity. Intracellular
essential amino acids accrue from the cooperative transport activity of ASCT2 and LAT1 as well as the proteolytic activity
of the ubiquitin-proteasome system (1) (Fuchs & Bode, 2005; Wu et al., 2009). Growth factors bind to receptor tyrosine
kinases at the cell surface, and these receptors recruit and activate class I phosphoinositide 3-kinase (PI3K) (2). Activated
PI3K converts membrane-bound phosphatidylinositol (4,5)-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)trisphosphate (PIP3), which attracts protein kinase B (PKB/Akt) and phosphoinositide-dependent kinase-1 (PDK1) to the
plasma membrane via their pleckstrin homology domains. This recruitment facilitates the phosphorylation and activation of
Akt by PDK1 (Wullschleger, Loewith, & Hall, 2006). Upon activation, Akt phosphorylates a broad range of targets
including mTORC1 and tuberous sclerosis complex 2 (TSC2) (Inoki, Li, Zhu, Wu, & Guan, 2002; Nascimento et al., 2010).
The combined signals from intracellular essential amino acids (1) and growth factors (2) remove the TSC1/2-mediated
inhibition of Ras-homolog-enriched-in-brain (Rheb) (Inoki, Zhu, & Guan, 2003). When bound to GTP, Rheb is in its active
form and cooperates with the Rag-Ragulator complex to activate and recruit mTORC1 to the lysosomal surface. mTORC1
is a serine threonine kinase that phosphorylates a variety of intracellular targets, including autophagy-related protein 13
(Atg13) and Unc-51 like autophagy activating kinase 1 (ULK1) of the macroautophagic pre-initiation ULK1/2 complex,
eukaryotic translation initiation factor 4E-binding protein (14E-BP1), ribosomal protein S6 kinase (p70S6K), and eukaryotic
elongation factor-2 kinase (eEF-2K) (Brown et al., 1995; Brunn et al., 1997; Hosokawa et al., 2009; Jung et al., 2009; Kim,
Kundu, Viollet, & Guan, 2011; Redpath, Foulstone, & Proud, 1996; L. Wang, Harris, Roth, & Lawrence, 2007). Together,
these phosphorylations lead to the activation of cap-dependent translation (3) and the suppression of autophagy (4). In
opposition, adenosine monophosphate (AMP)-activated protein kinase (AMPK) also contributes to this dynamic regulation
of intracellular energy homeostasis by phosphorylating raptor on mTORC1, the TSC1/2 complex, and the ULK1/2 complex
when the ratio of adenosine triphosphate to adenosine monophosphate (ATP:AMP) is low (Mihaylova & Shaw, 2011). This
action of AMPK inhibits mTORC1 and activates autophagy. Image created in reference to the respective sources listed
above.
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Many of the intermediate steps of the mTORC1 growth signaling model are still under
investigation, but there is strong evidence for a close relationship between mTORC1, amino acid
transport, and HCC. Currently, the Rag-Ragulator complex is thought to be a point of
convergence for cytosolic and lysosomic amino acid sensing (Sancak et al., 2010). SLC38A9, a
lysosomal amino acid transporter, has been identified as a putative arginine sensor, and its
activation mTORC1 signaling though the Rag-Ragulator complex is independent of its own
transport function (Rebsamen et al., 2015; S. Wang et al., 2015). The Ras-related protein Rab1A
has also been distinguished as a Rag-Ragulator activator, and overexpression of Rab1A in
primary human HCC has been correlated with poor prognosis (Chan, Carvalho, Riles, and
Zheng, 2000; Xu et al., 2015). A direct link between leucine availability and mTORC1 activation
was reported by studies that targeted leucyl-tRNA synthetase (LRS) with siRNA, and LRS was
shown to bind and activate the Rag-Ragulator complex in an amino acid-dependent manner (Han
et al., 2012). Another study revealed that Rag-Ragulator complex-mediated activation of
mTORC1 is dependent on the production of α-ketoglutarate from active glutaminolysis (Duran et
al., 2012). These studies highlight a small diversity of signals which can contribute to amino acid
sensing, and therefore, the mechanism by which ASCT2 and LAT1 drive mTORC1 activity may
be multifaceted and dependent on metabolic destination of ASCT2 and LAT1 substrates.
Given the enhanced expression of ASCT2 and LAT1 in HCC, their defined role in
mTORC1 signaling, and their potential to contribute to metabolic pathways that are distinctive to
the cancerous phenotype, the studies presented here were designed to assess the therapeutic
potential of targeting each transporter with stably maintained short hairpin RNA (shRNA) and
CRISPR-Cas9 gene editing methods. While past studies using an inducible antisense RNA
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system clearly implicated ASCT2 as a viable therapeutic target in HCC cells, the use of a viral
shRNA encoding vector was implemented here because it is a more tracTable modality for in
vivo applications. Conversely, the CRISPR-Cas9 gene editing system can’t be applied in vivo,
but this method of targeting was employed here because it surpasses the efficacy of shRNAmediated methods of gene suppression and can facilitate a deeper investigation into the role of
ASCT2 and LAT1 in HCC.
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CHAPTER 1: shRNA-MEDIATED KNOCKDOWN OF ASCT2 AND LAT1

Introduction

Former Ventures in Targeting ASCT2

The precursory research that served as a launch point for this project used several
different molecular approaches to target and suppress ASCT2 expression in HCC. The
aforementioned study using an inducible antisense ASCT2 RNA was the first to target ASCT2 at
the transcriptional level of expression (Fuchs et al., 2004). In this work, two customized plasmid
vectors (pGene/V5-HisA and pSwitch) were co-transfected into SK Hep cells, a mesenchymal
type HCC cell line, and stably maintained with two selective antibiotics, hygromycin B and
zeocin. The pGene/v5-HisA plasmid encodes an antisense ASCT2 sequence (~1.3 kb in length)
which has an 82% complementarity to the endogenous ASCT2 mRNA transcript (base pairs 8722205). The design of the promoter region upstream of the antisense sequence is exclusive to
binding by a chimeric transcription factor, GeneSwitch, which is encoded on the second plasmid,
pSwitch. The GeneSwitch transcription factor must be bound to an inducing agent known as
mifepristone (MFP), a synthetic analogue to progesterone, to assume its active conformation.
Therefore, in the presence of MFP, the GeneSwitch protein is able to drive transcription of the
ASCT2 antisense sequence on the pGene/v5-HisA plasmid, and then this antisense transcript can
be used by the cell’s resident RNA interference (RNAi) machinery to target and destroy ASCT2
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endogenous mRNA transcripts. Briefly, with regards to the underlying mechanism of ASCT2
mRNA suppression, the antisense RNA is believed to form double-stranded complex with the
endogenous ASCT2 mRNA transcript through complementary base-pairing. This doublestranded RNA (dsRNA) complex is then recognized by a cytosolic endoribonuclease called
DICER which cleaves the long dsRNA into small double-stranded fragments called microRNA
(miRNA) duplexes (Bernstein, Caudy, Hammond, and Hannon, 2001). These fragments are
subsequently recognized by a large ribonucleoprotein complex called the RNA-induced silencing
complex (RISC). RISC mediates the degradation of one strand of the miRNA duplex and
employs the remaining strand in its nucleolytic active site to specifically hybridize and degrade
(or sequester in some cases) complementary, endogenous ASCT2 mRNA templates (Hammond,
Bernstein, Beach, and Hannon, 2000). DICER and RISC are the principal members of a
conserved pathway known as the RNA interference (RNAi) pathway, and it is believed that this
mechanism of RNA processing initially evolved as an anti-viral defense in early single-celled
eukaryotes (Umbach and Cullen, 2009). The discovery of the RNAi pathway has led to the
development of many RNAi-based tools that exploit this pathway’s ability to degrade a wide
range of RNA targets depending only on the specificity of the priming miRNA’s sequence.
The antisense RNA study was successful in SK Hep cells, and the reductions in ASCT2
mRNA and protein coincided with apoptotic signaling through caspase-2 and caspase-9 as well
as cell death within 48 hours of MFP induction. Furthermore, ASCT2 knockdown using this
system stimulated apoptosis in a more controlled and rapid mechanism as compared to cellular
death resulting from glutamine starvation alone. Despite these promising results, applying the
antisense RNA system to an in vivo model is untenable. Cationic lipid-based delivery systems,
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such as the one used to co-transfect SK Hep, are systemic in nature, and these systems increase
the potential for off-target effects in healthy tissues which may depend on ASCT2 expression for
normal physiological functions (F. Liu, Qi, Huang, and Liu, 1997). Additionally, the successful
delivery of both vectors to cancerous tissue in a mouse model would be challenging, so this work
led to a search more tracTable systems of ASCT2-targeted RNAi that could be employed in vivo.
The next attempt to target and suppress ASCT2 expression in HCC cells utilized four
short interfering RNA (siRNA) designs, and these siRNAs were screened for silencing efficiency
in SK Hep cells (Fuchs et al. unpublished data). Total cellular RNA was isolated by a one-step
acid phenol-guanidinium method and evaluated by northern blot analysis. A titration curve was
performed with each siRNA design, and a concentration of 25-50 nM of siRNA-1 was found to
be the most effective siRNA design, demonstrating an 80% reduction of ASCT2 mRNA when
normalized to β-actin mRNA expression. However, the same ASCT2-targeted siRNA designs
were used again for later ASCT2-targeted experiments, and the substantial ASCT2 suppression
could not be reproduced (Finger, 2011).
The siRNA-mediated method of suppression is advantageous because it can generate a
robust knockdown of the target mRNA, but the effects are transient because siRNA is introduced
in a dose-dependent manner and is not stably maintained through an expression vector or
genomic modification. In clinical applications, it would be necessary to administer siRNA-based
therapeutics repetitively to patients, making implementation costly and impractical (Aagaard and
Rossi, 2007). There is also evidence that the duration siRNA-mediated silencing is dependent on
the proliferative rate of the host cell, and suppression of target genes is sustained for a shorter
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period of time in rapidly diving cells (Bartlett and Davis, 2007). This is particularly important in
the context of therapeutic development for aggressive cancers.
Alternatively, targeted mRNA suppression mediated by shRNA transcribed from plasmid
vectors has shown more potential in its potency and is inherently less transient than siRNAmediated systems (Takahashi, Yamaoka, Nishikawa, and Takakura, 2009). With this in mind,
another forerunner experiment implemented three unique plasmid constructs which encoded
shRNA sequences targeted to three different 19-21 bp regions of the endogenous ASCT2 mRNA
transcript (Finger, 2011). These plasmids also contained a doxycycline (Dox)-inducible promoter
and a selecTable hygromycin resistance sequence. A large panel of human heptoma cell lines
was used (Hep G2, Hep3B, Huh7, SK Hep-1, Focus, SNU2234, SNU2235, SNU2236,
SNU2237, and SNU2238), and after the transfected hepatoma cell lines were treated with the
Dox inducing agent, ASCT2 mRNA and protein expression were analyzed by northern and
western blot respectively. In this study, the shRNA plasmids failed to produce a discernible
reduction in ASCT2 protein, and the cells demonstrated a very minimal reduction in ASCT2
mRNA levels.

Targeting ASCT2 and LAT1 with the GIPZ shRNAmir Translentiviral Vector

This dissertation project was designed to target and suppress both ASCT2 and LAT1
transporter expression in HCC. The first technique applied to this goal was based in RNAi
technology comparable to the experiments that pioneered targeting of the just the ASCT2
transporter. Here two HCC cell lines, epithelial type Hep 3B and mesenchymal type SK Hep
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cells, were stably transfected with unique lentiviral-based plasmid vectors, each encoding
shRNAmir sequences designed to target endogenous ASCT2 and LAT1 mRNA transcripts. The
translentiviral plasmid vector used in this study is a proprietary pGIPZ shRNAmir transfer vector
designed by Open Biosystems, a division of Thermo Scientific, and the design is based on
lentiviral vectors designed previously by Kappes and Wu (Kappes and Wu, 2001; Wu et al.,
2000; Wu et al., 2001). Please see the Materials and Methods section for proprietary information
about constitutive sequences. The architecture of this particular plasmid vector is tailored for
compatibility to both transfection and transduction methods, and for this reason it is well-suited
for both in vitro and in vivo applications (Figure 3). This plasmid vector’s HIV-1-derived
lentiviral integration sequences, the 5’ long terminal repeat (5’LTR) and self-inactivating 3’ long
terminal repeat (3’sinLTR) regions, facilitate sTable transgenic transformation and long term
expression the intervening genes: specifically two reporter genes, turbo green fluorescent protein
(tGFP) and puromycin resistance (PuroR), as well as the customized effector shRNAmir
sequence responsible for target gene suppression.

Figure 3. General illustration of the GIPZ shRNAmir translentiviral plasmid vector design. Relevant abbreviations: 5’
long terminal repeat (5’LTR), central polypurine tract (cPPT), human cytomegalovirus promoter (CMV), turbo green
fluorescent protein (tGFP), internal ribosomal entry site (IRES), puromycin resistance (Puro R), microRNA-adapted shRNA
(shRNAmir), woodchuck hepatitis post-transcriptional regulatory element (WRE), 3’ self-inactivating long terminal repeat
(sinLTR), amplicillin resistance (Amp R), and bacterial origin of replication (pUC Ori). Thermo Scientific Open Biosystems
expression arrest GIPZ lentiviral shRNAmir [technical manual]. 2009. Thermo Scientific.
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Traditionally, RNA polyermase III (Pol III) promoters have been exploited in shRNA
vector designs because Pol III generates potent, sustained silencing due distinct initiation and
termination sites (Paddison, Caudy, Bernstein, Hannon, and Conklin, 2002). However, this
robust Pol III-driven shRNA expression is thought to occasionally cause oversaturation of the
cellular RNAi processing machinery which may lead to toxicity (Lebbink et al., 2011).
Alternatively, the use of RNA polymerase II (Pol II) promoter sequences has shown promise in
the reducing the risk of toxicity, perhaps because its initiation and termination sites are less welldefined (Aagaard and Rossi, 2007; Giering, Grimm, Storm, and Kay, 2008). The pGIPZ
shRNAmir plasmid vector design contains the latter Pol II promoter sequence labeled in Figure 3
as CMV, a cytomegalovirus promoter. When expressed, tGFP protein functions as a visual
reporter of downstream shRNAmir expression, where successfully transfected cells will emit a
characteristic green fluorescence at a maximum wavelength of 502 nm. Downstream of the tGFP
gene, an internal ribosome entry site (IRES), functions to recruit the host cell’s ribosomal
complex to the polycistronic mRNA transcribed from this gene complex, and this action
promotes translation that is independent of 5’-terminal 7-methyl guanine cap-induced translation
(Mokrejs et al., 2010). The PuroR gene encodes a protein called puromycin-N-acetyltransferase,
and this enzyme imparts puromycin resistance to the host cell by catalyzing a deactivating
acetylation an amino group on the puromycin antibiotic molecule (Vara, Perez-Gonzalez, and
Jimenez, 1985). The WRE sequence is a woodchuck post-transcriptional regulatory element
originally obtained from the woodchuck hepatitis virus (WHV), and WRE functions to enhance
transcription of the genes upstream. There are three proposed mechanisms for how WRE
accomplishes this function: it may enhance (1) the nuclear export of RNA transcripts, (2) the
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3’ cleavage and poly-adenylation of RNA transcripts, or (3) the condensation of protective RNAprotein complexes that shield the transcript from nuclear degradation (Zufferey, Donello, Trono,
and Hope, 1999). The central polypurine tract (cPPT) sequence upstream of the CMV promoter
is derived from the human immunodeficiency virus type-1 (HIV-1), and cPPT enhances
translocation of the plasmid vector into the nucleus through a structure called a central DNA flap
(Van Maele, De Rijck, De Clercq, and Debyser, 2003).
Figure 4 is a more comprehensive map of the pGIPZ shRNAmir lentiviral plasmid vector,
provided here as an additional reference. The full pGIPZ plasmid vector, including the
shRNAmir sequence, is 11,774 bp in length. Figure 4 illustrates bacterial and viral origins of
replication in black, functional lentiviral sequences in magenta, promoter regions in green,
regulatory elements in gold, mammalian and bacterial antibiotic resistance genes in orange,
turboGFP reporter gene in grey, and unique restriction enzyme sites in blue.
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Figure 4. Comprehensive illustration of the GIPZ shRNAmir translentiviral plasmid vector design. Thermo
Scientific Open Biosystems expression arrest GIPZ lentiviral shRNAmir [technical manual]. 2009. Thermo Scientific.
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When the effector shRNAmir sequence is transcribed in the host cell, a miR30-like
primary transcript is produced (Figure 5). The sequences that flank the complementary senseantisense (black and red, respectively) duplex are designed to mimic endogenous primary
miRNA transcripts (pri-miRNA), and this design is believed to facilitate an enhanced interaction
with functional enzymes of the RNAi pathway (Aagaard and Rossi, 2007). In the nucleus, a class
2 ribonuclease III enzyme known as Drosha is responsible for converting the full length
shRNAmir to a precursor miRNA (pre-miRNA) by catalyzing the cleavage and removal of the
blue sequences on the left. In the cytoplasm, the aforementioned endoribonuclease Dicer is
responsible for converting the pre-miRNA to a miRNA by catalyzing the cleavage and removal
of the green looped sequences on the right. Another noteworthy feature of this design is a
destabilizing mismatch on the 5’-end of the antisense strand (in red). This mismatch is believed
to encourage the preferential selection and incorporation of the antisense strand into the RNAinduced silencing complex (RISC) and control for undesired off-target effects that may result
from the incorporation of the sense strand of the miRNA duplex (Ge et al., 2010). The general
mechanism of shRNAmir-mediated mRNA targeting is illustrated in Figure 6.
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Figure 5. Illustration of shRNAmir design. Thermo Scientific Open Biosystems expression
arrest GIPZ lentiviral shRNAmir [technical manual]. 2009. Thermo Scientific.
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Figure 6. Illustration of the GIPZ shRNAmir mechanism of silencing. Transfection with the lentiviral GIPZ plasmid
vector generates the sTable genomic integration of a gene complex which encodes turbo green fluorescent protein (tGFP),
puromycin resistance (PuroR), and a unique shRNAmir sequence. The polycistronic mRNA transcript from this gene
complex is first cleaved by the DROSHA complex in the nucleus and then again by the DICER complex in the cytoplasm,
to generate a miRNA duplex. The antisense strand of the miRNA duplex is then recruited to the RNA-induced silencing
complex (RISC), which utilizes the antisense sequence to target complementary endogenous mRNA targets for degradation.
The end result is the inhibition of target mRNA translation in a mechanism that is shRNAmir-sequence dependent. Image
created with with reference to Thermo Scientific Open Biosystems expression arrest GIPZ lentiviral shRNAmir [technical
manual]. 2009. Thermo Scientific.
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Table 1 is a list of the specific sense/antisense sequence identities that were used in each
shRNAmir design in order to target either ASCT2 or LAT1 for suppression in this study. Using
these inserts, five unique regions of the ASCT2 mRNA transcript, four unique regions of the
LAT1 mRNA transcript, and one region of the glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) mRNA transcript (a commercially tested positive control) were targeted. Herein, the
name of each cell line generated from successful transfection with the five GIPZ ASCT2targeted plasmid vectors will receive the identifications A1, A2, A3, A4, and A5, as denoted on
Table 1. Likewise, cell lines generated from successful transfection with the four pGIPZ LAT1targeted plasmid vectors will receive the identifications L1, L2, L3, and L4 as denoted on Table
1. A control GIPZ plasmid vector containing a scrambled shRNAmir sequence, with no sequence
homology to any known mammalian gene, was also used for transfection in this study. Cell lines
generated from transfection with this plasmid vector will receive the identification NS to
designate these cell lines as non-silencing.
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Table 1. GIPZ shRNAmir sequences and their endogenous mRNA target regions.
Target Protein Open Biosystems Clone
(Gene ID)
ID
ASCT2
(NM_005628)

V3LHS_393625
(A1)
V3LHS_393624
(A2)
V3LHS_393623
(A3)
V3LHS_393622
(A4)
V2LHS_56725
(A5)

LAT1
(NM_003486)

V2LHS_172487
(L1)
V3LHS_353675
(L2)
V3LHS_353676
(L3)
V3LHS_353679
(L4)

GAPDH
(NM_002046.3)
Non-Silencing

V3LHS_382663
(GAPDH)
CAT#:RHS4346
(NS)

Sense Sequence (5’-3’)
Antisense Sequence (5’-3’)
CGCTCATACTCTACCACCT
AGGTGGTAGAGTATGAGCG
AGCCTTTCGCTCATACTCT
AGAGTATGAGCGAAAGGCT
CGCTTCTTCAACTCCTTCA
TGAAGGAGTTGAAGAAGCG
CGGTCCTGTACCGTCCTCA
TGAGGACGGTACAGGACCG
GGATTATGAGGAATGGATA
TATCCATTCCTCATAATCC
GTACGAATCTCATCCCTCA
TGAGGGATGAGATTCGTAC
ACGACCGTCCTGTGTCAGA
TCTGACACAGGACGGTCGT
TGGATCGAGCTGCTCATCA
TGATGAGCAGCTCGATCCA
GGGGTCTGGTGGAAAAACA
TGTTTTTCCACCAGACCCC
TGGTTTACATGTTCCAATAT
ATATTGGAACATGTAAACCA
ATCTCGCTTGGGCGAGAGTAAG
CTTACTCTCGCCCAAGCGAGAG

mRNA
Sequence
Targeted
1224 – 1242
1217 – 1235
1389 – 1407
2013 - 2031
2296 - 2314
1761 - 1779
1546 - 1564
472 - 490
1491 - 1513
230-248
N/A
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In order to better understand the specific regions on the endogenous target mRNA
transcripts that could hybridize with the shRNAmir designs, Sfold software for statistical folding
of nucleic acids was used to generate models of mRNA secondary structure for ASCT2 and
LAT1. This software uses an algorithm that determines the probability of different RNA:RNA
self-interactions which produce secondary conformations. The algorithm is based on the
principles of Boltzmann probability-weighted density states and free energy distributions
determined from sampled structures (Ding et al., 2004). It is important to note that the accuracy
of the predicted secondary structure is limited due to variability in ion-mediated electrostatic
interaction, protein-assisted mRNA folding, and stabilizing tertiary RNA interactions (Chen,
2008; Gardner and Giegerich, 2004). The secondary mRNA structure models selected for
Figures 7 and 8 are the minimum free energy (MFE) structures and are only intended to illustrate
the general range of mRNA sequence targets achieved by using the different shRNAmir designs
from Table 1.
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Figure 7. shRNAmir target regions on the ASCT2 mRNA. MFE ASCT2 mRNA
fold prediction was generated with Sfold software (Ding, Chan, & Lawrence, 2004).

Figure 8. shRNAmir target regions on the LAT1 mRNA. MFE LAT1 mRNA
fold prediction was generated with Sfold software (Ding, Chan, & Lawrence, 2004).
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Materials and Methods

Mammalian Cell Culture

The human hepatoma cell lines used in this study were Hep 3B and SK Hep cells
(American Type Culture Collection, Rockville, MD). Cell lines were maintained at 37°C in a
humidified atmosphere of 5% CO2-95% air in Dulbecco’s Modified Eagle Medium (DMEM,
4.5 mg/ml D-glucose)(Gibco, Grand Island, NY) supplemented with 10% triple 0.1 μm filtered
fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA), 2 mM L-glutamine (Thermo
Scientific, Waltham, MA), 1% antibiotic/anti-mycotic solution (100 U/ml Penicillin G, 100
μg/ml Streptomycin, and 0.25 μg/ml Amphotericin)(Thermo Scientific). Cell count
measurements were performed using an Invitrogen™ Tali™ Image-based Cytometer (Thermo
Scientific) and a hemocytometer slide (Hausser Scientific Co., Horsham, PA).

Plasmids, Transfection, and Antibiotic Selection

The pGIPZ plasmid vectors are a product of Open Biosystems (Huntsville, AL). A
comprehensive map of the pGIPZ transfer vector plasmid can be found in Figure 4. The five
shRNAmir sequences selected to target ASCT2 have following clone IDs: V3LHS_393625,
V3LHS_393624, V3LHS_393623, and V3LHS_393622, and V2LHS_56725, and these
shRNAmir designs are referred to herein as A1, A2, A3, A4, and A5, respectively. The four
shRNAmir sequences selected to target LAT1 have the following clone IDs: V2LHS_17487,
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V3LHS_353675, V3LHS_353676, and V3LHS_353679, and these shRNAmir designs are
referred to herein as L1, L2, L3, and L4, respectively. The clone ID of the single shRNAmir
sequence selected to target GAPDH as a positive control is V3LHS_382663. The catalogue
number of the scrambled shRNAmir sequence that served as a non-silencing (NS) negative
control is RHS4346. The shRNA and target mRNA binding sites were visualized using Sfold
Software (Ding et al., 2004)(Figures 7 and 8). All specific shRNAmir sense and anti-sense
sequences can be found in Table 1. All pGIPZ plasmid vectors were purchased from Open
Biosystems in PrimePlus Escherichia coli (E. coli) stocks (60% glycerol) and stored at -80°C.
A working concentration of each plasmid construct was created by growing up 50 ml
cultures of PrimePlus E. coli in low salt LB-Lennox broth containing 8% glycerol and 100 μg/ml
ampicillin (Fisher Scientific, Fair Lawn, NJ). The cultures were incubated at 37°C until reaching
a density reading in the range of 2-4 OD600 units. A PureYield™ Promega Plasmid Midiprep kit
was used to extract and purify plasmid stocks according to the manufacturer protocol (Promega,
Madison, WI). Plasmid concentrations were measured with a Nanodrop 2000 Micro-Volume
UV-Vis Spectrophotometer (Thermo Scientific), and each plasmid stock was stored at -20°C.
Transfections were performed using either a proprietary lipo-polymeric transfection
reagent called Arrest-In or electroporation using the Neon® Transfection System (Thermo
Scientific). Transfections were carried out in serum-free and antibiotic-free Opti-MEM® or
Resuspension Buffer R (a proprietary formulation) respective of the technique. For lipopolymeric-based transfections, optimization was carried out by testing a range of DNA to
transfection reagent ratios. For electroporation-based transfections, optimization was carried out
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by testing a range of DNA concentrations with the concentration of cells held constant (5 x 106
cells/ml). All stably transfected hepatoma cells were maintained under selective pressure in
growth media supplemented with 0.5 μg/ml puromycin for SK Hep and 3.0 μg/ml for Hep 3B
(Gibco). A kill curve was implemented for each cell line to determine the concentration of
puromycin that kills 100% of the cell population within three days of the initial antibiotic
addition. TurboGFP expression was visualized and imaged using a Zeiss LSM PASCAL
confocal laser scanning microscope with a FITC excitation/dichroic/emitter filter and an EVOS®
FLoid® Cell Imaging Station.

RNA Isolation and RT-qPCR

All cell lines were plated 1 x 106 cells per 150 mm plate. When the cells reached 80-90%
confluence, an RNA preparation was performed using TRIzol® reagent (Life Technologies,
Grand Island, NY) according to the manufacturer instructions, and this was followed by an
alcohol precipitation to concentrate the samples. To check for 28S and 18S band quality, the
samples were run on a 1% agarose gel, and then a Nanodrop 2000 Micro-Volume UV-Vis
spectrophotometer was used to quantify RNA concentrations. Concentrated RNA samples were
stored at -80°C until use. One µg of total RNA was used from each sample for the subsequent
reverse transcription reactions, and these reactions contained reverse transcriptase, oligo(dT), 5X
reaction buffer, MgCl2, RNasin, dNTP (all from Promega, Madison, WI). RT-qPCR was
performed using proprietary TaqMan® Gene Expression Assay primers exclusive to human
ASCT2, LAT1, alanine-serine-cysteine transporter 1 (ASCT1), sodium-dependent neutral amino
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acid transporter 2 (SNAT2), large neutral amino acid transporter 2 (LAT2), glutamine synthetase
(GLUL), and cystine-glutamate transporter (XCT) mRNA transcripts, and all measurements
were normalized to two housekeeping genes (HKG, also known as reference genes): TATAbinding protein (TBP) and hydroxymethylbilane synthase (HMBS) (Thermo Scientific). All
primer sets selected spanned intragenic regions (introns) in the genomic sequences for each gene.
The 2-ΔΔCt method was used to calculate the fold difference in expression and are represented
herein relative to NS controls for each parent cell line. Greater than a two fold increase in
expression was considered significant. All RT-qPCR reactions were carried out using an
Eppendorf Mastercycler® ep realplex (Eppendorf, Hauppauge, NY). Each run was performed a
minimum of three times, and within each run, each sample was run in triplicate for each target
transcript. These experiments strictly complied with MIQE (Minimum Information about
Quantitative Real-Time PCR Experiments) guidelines.

Antibodies and Western Blot Analysis

For western blots that measured ASCT2, LAT1, GAPDH, yes-associated protein 1
(YAP), GLUL, and glucose transporter 1 GLUT1 protein expression, total cellular protein
lysates were prepared using 2X Laemmli lysis buffer (2% SDS (Sigma, St. Louis, MO), 62.5
mM Tris-HCl [pH 6.8], and 1% protease inhibitor cocktail (Thermo Scientific)). Total cellular
protein concentration was measured with a Nanodrop 2000 Micro-Volume UV-Vis
spectrophotometer, and equal protein from each sample was prepared for vertical electrophoresis
in 2% SDS, 10% glycerol, 62.5 mM Tris-HCl (pH 6.8), 0.05% bromophenol blue (Fisher
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Scientific), and 50 mM dithiothreitol (DTT) (Fisher Scientific). All lysis preps were performed
in 6-well plates when the monolayer of cellular growth had reached confluence.
For phosphorylation specific western blots that measured total and phosphorylated 4EBP1(TOTAL or T37/46) and p70S6K(TOTAL or T389) protein concentration, total cellular protein lysates
were prepared using a lysis buffer which contained phosphatase inhibitors to preserve the
phosphorylation state of the proteins of interest (10 mM Tris [pH 6.8], 1 mM EDTA, 5 mM
EGTA, 0.5% NP40 (US Biological, Cleveland, OH), 0.1% Triton X 100, 1 mM sodium
orthovanadate (Sigma), 50 mM β-glycerophosphate (Sigma), and 1% protease inhibitor cocktail
(Thermo Scientific)). Total cellular protein concentration was measured with a bicinchoninic
acid (BCA)(Pierce Chemical, Rockford, IL) chemical assay and an Epoch Microplate
Spectrophotometer. Equal protein from each sample was prepared for vertical electrophoresis in
the same buffer that was used for lysis supplemented with 10% glycerol, 0.05% bromophenol
blue, and 50 mM dithiothreitol (DTT). All of the total cellular protein lysates analyzed in 4EBP1(TOTAL or T37/46) and p70S6K(TOTAL or T389) western blots were run in parallel with a positive
control cell lysate from MCF7 cells treated with insulin provided by Cell Signaling Technologies
(Danvers, MA).
For all western blots, vertical electrophoresis was run on precast 4-20% MiniPROTEAN® TGX™ polyacrylamide gels (Bio-Rad, Hercules, CA) at 150V for 45 minutes, and
protein samples were transferred to Immobilon-P polyvinylidene difluoride (PVDF) membranes
(Millipore, Bedford, MA) at 75V for 90 minutes. After one hour of incubation in blocking buffer
(5% bovine serum albumin (BSA), 0.1% Tween-20 in Tris-buffered saline ((TBS) 150 mM
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NaCL + 20 mM Tris [pH 7.5]) at room temperature, the PVDF membranes were incubated
overnight at 4oC with the appropriate primary antibody in blocking buffer. The membranes were
then incubated with secondary antibody in blocking buffer for one hour at room temperature.
Immunoreactive bands were visualized by adding 10 ml of chemiluminescent substrate (1X
LumiGLO® and 1X peroxide)(both from Cell Signaling Technologies) and incubating for a 1
minute at room temperature, followed by imaging with a G:Box Chemiluminescence Imager
(Syngene, Frederick, MD) and GeneSnap image acquisition software (Syngene). The molecular
size of the chemiluminescent bands was determined by comparison to a biotinylated ladder (Cell
Signaling Technologies), and the results were quantified using ImageJ Software.
Primary polyclonal rabbit IgG antibodies against LAT1 were obtained from Abcam
(Cambridge, MA). Primary IgG antibodies against GLUT1 and xCT were obtained from Thermo
Scientific. All other primary monoclonal rabbit IgG antibodies were obtained from Cell
Signaling Technologies. Secondary HRP-conjugated goat, anti-rabbit IgG antibodies were
obtained from Cell Signaling Technologies as well. No deviation was made from the
recommended antibody concentrations applied to each blot during hybridization steps.
For western blots that measured ASCT2, LAT1, GAPDH, YAP, GLUL, and xCT protein
expression, band intensity was quantified using ImageJ and normalized to the band intensities of
the loading controls measured on the same blot. For western blots that measured total and
phosphorylated 4E-BP1(TOTAL or T37/46), a shift in location, a change in kDa weight of the 4E-BP1
protein due to phosphorylation, was the principal focus. So banding patterns for 4E-BP1(TOTAL or
T37/46)

western blots were qualitatively evaluated.

31

Glutamine, Leucine, and Arginine Transport Analysis
All cell lines were plated at a density of 1 x 105 cells/well in 24-well culture plates and
allowed to grow to 80-90% confluence, normally one or two days later. Tritium was used as a
radiotracer for glutamine (L-[3H]Gln), leucine (L-[3H]Leu) and arginine (L-[3H]Arg), each at a 3
μCi/ml concentration in the amino acid uptake mixes (Amersham, Arlington Heights, IL).
Uptake was performed in the presence of unlabeled L-Gln, L-Leu, or L-Arg, each at a 10 μM
concentration. All transport measurements were carried out at 37°C and were terminated after 30
seconds by three rapid washes with an ice-cold phosphate-buffered saline (PBS) solution.
Intracellular radiolabeled amino acid (glutamine, leucine, or arginine, with respect to the
experiment) was extracted by treating the cells with lysis buffer (0.2 ml/well of 0.2% SDS and
0.2 N NaOH) for 30 minutes, and 0.1 ml of the lysate was neutralized with 10 μl 2 N HCl and
analyzed with scintillation spectrophotometry in a Tri-Carb B2910TR Liquid Scintillation
Analyzer and associated QuantaSmart™ Software (PerkinElmer, Akron, OH). The remaining
lysate was used for the determination of cellular protein concentrations by a BCA assay and
subsequent analysis on an Epoch Microplate Spectrophotometer. Initial rate uptake of glutamine,
leucine, and arginine transport were calculated from the counts per minute (cpm) per sample and
the specific activity of each uptake mix (in cpm/nmol), and these measurements were normalized
to cellular protein content in a Microsoft Excel spreadsheet program. For glutamine uptake
studies, transport values obtained in the absence of extracellular Na+ (diffusion and Na+independent uptake) were subtracted from those in the presence of Na+ (total uptake) to yield
Na+-dependent rates that are reported in units of nanomoles per milligram protein per 30 s.
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In some experiments, system A glutamine transport inhibitor, 2-methylaminoisobutyric
acid (MeAIB) (Sigma) was used at a concentration of 5 mM in the uptake mixture to
differentiate between system A and system ASC-mediated glutamine transport. Other inhibitors
used include 1 mM glutaminyl-para-nitroanilide (GPNA; MP Biomedicals, Santa Ana, CA), an
ASCT2-specific inhibitor and 5 mM 2-amino-2-norbornanecarboxlic acid (BCH; Sigma), a
LAT1-specific inhibitor. All transport values depicted are the average ± SD of four separate
determinations. When applicable, in order to compare transport values between cluster plates,
NS controls for each parent line were set to a value of 1 and all other transport values were
mathematically adjusted to reflect this change.

Proliferative Assays - MTT Analysis

SK Hep and Hep 3B cells were plated at a density of 2.0 x 103 cells/well and 8.0 x 103
cells/well respectively in a 48-well plate. The cells grew to 10-20% confluence (T0) before the
plates were analyzed with a methylthiazol tetrazolium (MTT) assay at the following terminal
time points: 0, 24, 48, 72, 96, 120, 144, and 168 hours. When each plate was terminated, the cells
were washed with a 1X solution of phosphate buffered saline, followed by a three hour
incubation in a 0.5mg/ml solution of MTT in phenol red-free DMEM (4.5 mg/ml Dglucose)(Gibco) at 37 ̊C. After incubation, precipitated formazan crystals in each well were
solubilized with an acidic solution of 0.04 M HCl in absolute isopropanol. All absorbance
measurements (550nm-690nm) were taken using an Epoch Microplate Spectrophotometer.
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Proliferative Assays – Digital Image-Based Cytometry
SK Hep and Hep 3B cells were plated at a density of 4.0 x 103 cells/well and 1.6 x 104
cells/well, respectively, in 12-well plates. The cells grew to 10-20% confluence (T0) before the
plates were analyzed following a standard trypsinization and resuspension procedure and an
automated, digital cell count was performed at the following time points: 0, 24, 48, 72, 96, 120,
144, and 168 hours. For each measurement, a bracketed range of cell diameters was set 10-16 μm
to eliminate doublets and cellular debris from the count. Cell count measurements were
performed using an Invitrogen™ Tali™ Image-based Cytometer (Thermo Scientific).

mTORC1 Analysis

To evaluate the influence of select extracellular signals on mTORC1 activity, starvation
and repletion treatment steps followed a protocol similarly described by Nicklin et al., 2009.
Figure 9 summarizes the treatment steps used herein for the sake of clarity.

Figure 9. mTORC1 treatment steps. In order to remove extracellular stimulation from growth factors and amino acids, all cells
were deprived of FBS for 18-22 hours followed by a 3 hour amino acid starvation step. Cell lines were then differentially treated
with one of five experimental conditions for 1 hour. At each stage of the treatment series, total cellular lysate was prepared using
a lysis buffer which contained phosphatase inhibitors to preserve the phosphorylation state of all proteins of interest. This
protocol is a modification of the procedure performed by Nicklin et al., 2009.
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SK Hep and Hep 3B cells were plated at a density of 5.0 x 105 cells/well in 6-well plates,
and when this population was 80-90% confluent, the cells were deprived of FBS (serum-free
DMEM) for 18-22 hr in order to remove growth factor signaling from serum supplementation.
The cells were next incubated in FBS-free, amino acid-free sodium Krebs-Ringer bicarbonate
buffer (NaKRB) (MgSO4, KCl, KH2PO4 [monobasic], NaCl, Glucose, NaHCO3, phenol red, and
CalCl2) for 3 hours in order to remove extracellular amino acid signaling. At the end of the three
hour FBS and amino acid starvation time, the cells were differentially treated with: (1) NaKRB +
2 mM L-GLN + essential amino acids (EAA: histidine, isoleucine, leucine, lysine, methionine,
phenylalanine, threonine, tryptophan, and valine at normal physiological concentrations); or
NaKRB + GLN + EAA plus one of the following four additives: (2) 1 mM glutaminyl-paranitroanilide (GPNA; MP Biomedicals, Santa Ana, CA), an ASCT2 inhibitor; (3) 5 mM 2-amino2-norbornanecarboxlic acid (BCH; Sigma), a LAT1 inhibitor; (4) 20 nM rapamycin (LC
Laboratories, Woburn, MA), an mTORC1 inhibitor; or (5) EtOH vehicle control, followed by an
incubation time of 1 hour at 37°C. Total cellular lysate was prepared for each condition
(indicated by the microfuge tube symbol on Figure 9) according to the previously described
parameters for phosphorylation specific western blots in the Antibodies and Western Blot
Analysis section of Materials and Methods.

Drug Treatments

The following drug treatments were used in this study: (1) sorafenib (10 μM), an FDA
approved tyrosine kinase inhibitor used in the treatment of liver, kidney, and thyroid cancers;
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(2) metformin (10 mM), an FDA approved anti-diabetic drug treatment; (3) methionine
sulfoximine (MSO)(1.5 mM), a glutamine synthetase inhibitor; and (4) WZB117 (10 μM),
glucose transporter type 1 (GLUT1) inhibitor. The effect of each drug treatment on growth was
measured using an MTT assay, as previously described in the Proliferative Assays - MTT
Analysis subsection of Materials and Methods. SK Hep and Hep 3B cells were plated at a density
of 6.0 x 103 cells/well and 12.0 x 103 cells/well respectively in a 48-well plate. MTT
spectrophotometric measurements were taken before the drug treatments were added and at two
subsequent time points: 42 and 72 hrs.

Acridine Orange Staining and Confocal Microscopy

A qualitative assessments of the distribution intracellular acidic compartments were
performed with an acridine orange (AO) dual fluorescence stain (Sigma) and confocal
microscopy. Cells were plated on sterile glass coverslips at a density of 5.0 x 105 cells/well in 6well plates, and when this population was 80-90% confluent, the cells were stained with AO at a
concentration of 1 μg/ml and incubated for 1 minute at 37°C. After incubation, the coverslips
were removed from the 6-well plates and mounted face-down on glass microscope slides
customized with small pedestals to allow space for 50 μl of growth medium during the imaging
process. The cells were imaged using a Zeiss LSM PASCAL confocal laser scanning microscope
with a fluorescein isothiocyanate (FITC)-rhodamine excitation/dichroic/emitter filter (LP560; BP
505-530) and associated LSM5 software. Differential interference contrast (DIC) images were
captured simultaneously with fluorescence images generated from the FITC-rhodamine filter,
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and these three images were used to produce a digital overlay of the three spectra by the LSM5
software.

Results

shRNA-Mediated ASCT2 and LAT1 Knockdown

Hep 3B and SK Hep cell lines transfected with the GIPZ lentiviral shRNAmir plasmid
vectors were grown under puromycin-selective conditions and were positive for tGFP reporter
gene expression (Figures 10 and 11). Each cell line was imaged with an EVOS® FLoid® cell
imaging fluorescent microscope using transmitted light and green fluorescence (482/18 nm
excitation) channels. These two channels were used to create composite digital overlay images to
assess tGFP expression across the populations of each cell line. Overall, puromycin antibiotic
selection was successful in eliminating cells that did not express tGFP from each population of
transfected Hep 3B and SK Hep cells. Though, some heterogeneity in the intensity of tGFP
expression was observed within the populations of each transfected cell line. Variable tGFP
expression may indicate that there is variation in the intensity of transciption of the genomically
integrated transgenic region between individual cells in a given population. Therefore,
subsequent mRNA, protein, and transport activity analyses of these populations were only
capable of estimating average changes across these cell line populations and do not have single
cell resolution.

37

Figure 10. tGFP expression in the shRNA-mediated knockdown Hep 3B cell lines. Reporter gene turbogreen fluorescent protein (tGFP; excitation/emission = 482/502 nm) expression in stably transected Hep 3B
was visualized using an EVOS® FLoid® cell imaging fluorescent microscope with an 482/18 nm excitation
preset. These images are the composite digital overlay of the transmitted light and green fluorescence
channels for each cell line.
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Figure 11. tGFP expression in the shRNA-mediated knockdown SK Hep cell lines. Reporter gene turbogreen fluorescent protein (tGFP; excitation/emission = 482/502 nm) expression in stably transected SK Hep
was visualized using an EVOS® FLoid® cell imaging fluorescent microscope with an 482/18 nm excitation
preset. These images are the composite digital overlay of the transmitted light and green fluorescence
channels for each cell line.
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Following the initial qualitative assessment of tGFP expression, the knockdown of
ASCT2 and LAT1 mRNA was assessed by quantitative reverse transcriptase polymerase chain
reaction (RT-qPCR) analysis (Figure 12). A greater degree of ASCT2 mRNA knockdown was
achieved overall in the stably transfected SK Hep cell lines relative to the Hep 3B cell lines. In
the Hep 3B subset of ASCT2-targeted cell lines (HA1-HA5), mRNA expression was diminished
by 15-33%, and HA2, HA3, and HA4 were roughly equal in their levels of ASCT2 mRNA
knockdown (Fig. 12A). In the SK Hep subset of ASCT2-targeted cell lines (SA1-SA5), mRNA
expression was diminished by 49-96%, and SA2 and SA5 exhibited the most dramatic levels of
ASCT2 mRNA knockdown (Fig. 12C).
RT-qPCR analysis of LAT1 mRNA expression showed very similar overall patterns of
knockdown across both Hep 3B and SK Hep subsets of LAT1-targeted cell lines. LAT1 mRNA
expression in LAT1-targeted Hep 3B cell lines (HL1-HL4) was diminished by 63-85%, and the
HL1 and HL2 cell lines demonstrated the greatest degree of knockdown (Fig. 12B). Likewise, in
the LAT1- targeted SK Hep cell lines (SL1-SL4), mRNA expression was diminished by 66-93%,
and the SL1 and SL2 cell lines demonstrated the greatest degree of knockdown (Fig. 12D).
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Figure 12. ASCT2 and LAT1 mRNA expression after shRNA-mediated knockdown in SK Hep cell lines and Hep 3B cell
lines. ASCT2 and LAT1 mRNA expression was measured by quantitative RT-PCR analysis as described in MATERIALS AND
METHODS. Each target mRNA expression level is represented as a geometric mean of three experimental RT-qPCR runs
relative to the expression level of both TBP and HMBS housekeeping genes (HKG). Hep 3B-derived ASCT2 knockdown cell
lines (HA1-HA5) (A) and LAT1 knockdown cell lines (HL1-HL4) (B) are shown relative to the non-silencing control cell line
for Hep 3B (HNS). SK Hep-derived ASCT2 knockdown cell lines (SA1-SA5) (C) and LAT1 knockdown cell lines (SL1-SL4)
(D) are shown relative to the non-silencing control cell line for SK Hep (SNS).

In order to support the results from RT-qPCR analyses, western blot analyses were
performed to measure changes in ASCT2 and LAT1 protein expression across the Hep 3B and
SK Hep transfected cell lines (Figures 13 and 14, respectively). These western blots confirmed
the A2 and A5 shRNAmir designs as the most effective in suppressing ASCT2 protein
expression in both Hep 3B and SK Hep (Fig. 13B and Fig. 14B, respectively). In the SK Hep
subset of ASCT2-targeted cell lines (SA1-SA5), the overall pattern of ASCT2 mRNA and
protein knockdown was very similar (Fig. 12C vs. Fig. 14B). Conversely, in the Hep 3B subset
of ASCT2-targeted cell lines (HA1-HA5), the overall pattern of ASCT2 protein knockdown (Fig.
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13B) was better matched to the pattern of ASCT2 protein knockdown observed in the western
blot for the SK Hep subset of ASCT2-targeted cell lines (Fig. 14B), rather than the pattern of
mRNA knockdown observed in the RT-qPCR analysis (Fig. 12A). The similarity of the ASCT2
protein knockdown pattern between the ASCT2-targeted subsets of Hep 3B and SK Hep
suggests that the efficiency of shRNA-mediated suppression of ASCT2 is dependent on the
unique shRNAmir sequence design, more so than cell line identity.
Western blot analyses of LAT1 protein expression in the Hep 3B and SK Hep subsets of
LAT1-targeted cell lines (HL1-HL4 vs. SL1-SL4) (Fig. 13C and Fig. 14C, respectively)
exhibited differing patterns of LAT1 protein knockdown when compared to the patterns of LAT1
mRNA knockdown observed these subsets from the RT-qPCR analyses (Fig. 12B and 12D,
respectively). In the Hep 3B HL1-HL4 subset, LAT1 protein expression was diminished to the
greatest extent in HL1 and HL3 (Fig. 13C). In SK Hep SL1-SL4 subset, LAT1 protein
expression was nearly undetecTable across all of the cell lines (Fig. 14C).
To control for the efficacy of the GIPZ shRNAmir silencing system, a lentiviral plasmid
vector encoding an shRNAmir against glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
was transfected into Hep 3B and SK Hep, and two sTable GAPDH-targeted cell lines were
generated, HGAPDH and SGAPDH respectively. In general, GAPDH protein expression was
variable across the array of Hep 3B-derived cell lines (Fig. 13D). Reductions in GAPDH protein
were evident in the HL3, HL2, HL4, and HGAPDH cell lines, whereas the HA3 and HA4 cell
lines demonstrated an increased level of GAPDH protein expression (Fig. 13D). Across the
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SK Hep-derived cell lines, a reduction in GAPDH protein expression was only evident in the
GAPDH-targeted cell line SGAPDH (Fig. 14D).
There has recently been an increased interest in the role of a transcription factor called
Yes-associated protein (YAP) in cancer, and this is due to new evidence linking YAP, along with
its partner protein, transcriptional co-activator with PDZ-binding motif (TAZ), to mTORC1,
LAT1, SNAT1 expression in HCC, which has generated attention to these proteins as potential
prognostic markers (Moroishi, Hansen, and Guan, 2015; Park et al., 2015). As a preliminary
examination of a potential negative feedback signal arising from LAT1 knockdown and affecting
cellular YAP concentrations, YAP protein expression was also evaluated in this set of western
blot analyses across the Hep 3B and SK Hep sets of transfected cell lines (Fig. 13E and Fig. 14E,
respectively). Overall, YAP protein expression was not significantly variable amongst ASCT2and LAT1-targeted cell lines, relative to the non-silencing (NS) and parent cell line controls.
Given this result, no further YAP analysis was performed in these cell lines.
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Figure 13. ASCT2, LAT1, GAPDH, and YAP protein expression in the shRNA-mediated knockdown
Hep 3B cell lines. Protein expression was measured by western blot analysis as described in MATERIALS
AND METHODS. The chemiluminescent bands for each target (ASCT2, LAT1, GAPDH, and YAP) are
shown in comparison to β-actin protein detected on the same blot to control for loading error (A). One image
for β-actin is shown for both GAPDH and YAP western blots because these proteins were detected on the
same blot. The band intensity of each target was quantified using ImageJ analysis software and normalized
to β-actin band intensity in each lane (B-E).
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Figure 14. ASCT2, LAT1, GAPDH, and YAP protein expression in the shRNA-mediated knockdown SK Hep
cell lines. Protein expression was measured by western blot analysis as described in MATERIALS AND
METHODS. The chemiluminescent bands for each target (ASCT2, LAT1, GAPDH, and YAP) are shown in
comparison to β-actin protein detected on the same blot to control for loading error (A). One image for β-actin is
shown for both GAPDH and YAP western blots because these proteins were detected on the same blot. The band
intensity of each target was quantified using ImageJ analysis software and normalized to the β-actin band intensity in
each lane (B-E).
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In order to support the preceding evaluations of mRNA and protein knockdown, initial
rate transport analysis was performed using tritium-radiolabeled L-glutamine and L-leucine
derivatives to determine the impact of shRNA-mediated transporter knockdown on the functional
activity of the ASCT2 and LAT1 transporters in each of the stably transfected cell lines. Overall,
there was a very similar pattern of reduction in Na+-dependent initial rate glutamine uptake
across the ASCT2-targeted Hep 3B and SK Hep cell lines (HA1-HA5 vs. SA1-SA5) (Fig. 15A
and B, respectively). Furthermore, the patterns of reduced initial rate glutamine uptake across
these cell lines closely corresponded to the patterns of reduced ASCT2 protein expression
observed in the same cell lines in earlier western blot analyses (Fig. 13B and 14B, respectively).
Initial rate leucine uptake was not considerably diminished in the LAT1-targeted subset
of Hep 3B cell lines (HL1-HL4), and the two best reductions in leucine uptake were
demonstrated by the HL1 and HL4 cell lines (Fig. 16A). Much more significant reductions in
leucine uptake were measured across the LAT1-targeted subset of SK Hep cell lines (SL1-SL4)
(Fig. 16B), and these diminished initial rate leucine uptake measurements are complementary to
the significantly reduced levels LAT1 protein expression observed in the same cell lines in
earlier western blot analyses (Fig. 14C).
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Figure 15. Na+-dependent glutamine (L-[3H]Gln) initial rate uptake in the shRNA-mediated ASCT2 knockdown Hep
3B and SK Hep cell lines. Transport of 10 μM L-glutamine was measured as described in MATERIALS AND METHODS.
Due to the Na+-dependence of ASCT2-mediated glutamine uptake, the transport values obtained in the absence of extracellular
Na+ (diffusion and Na+-independent uptake) were subtracted from those in the presence of Na+ (total uptake) to yield Na+dependent rates. In the first graph, Hep 3B-derived ASCT2 knockdown cell lines (HA1-HA5) are shown respective to the nonsilencing control cell line (HNS) and the Hep 3B parent line (A), and in the second graph SK Hep-derived ASCT2 knockdown
cell lines (SA1-SA5) are shown respective to the non-silencing control cell line (SNS) and the SK Hep parent line (B). In order
to compare transport values between cluster plates, NS controls for each parent line were set to a value of 1 and all other
transport values were mathematically adjusted to reflect this change. Data are the average of at least four separate
determinations ± SD. Asterisks (*) denote values that are statistically significant with a P value < 0.05.

47

Figure 16. Leucine (L-[3H]Leu) initial rate uptake in the shRNA-mediated LAT1 knockdown Hep 3B and SK Hep
cell lines. Transport of 10 μM L-leucine was measured as described in MATERIALS AND METHODS. In the first graph,
Hep 3B-derived LAT1 knockdown cell lines (HL1-HL4) are shown respective to the non-silencing control cell line (HNS)
and the Hep 3B parent line (A), and in the second graph SK Hep-derived LAT1 knockdown cell lines (SL1-SL4) are shown
respective to the non-silencing control cell line (SNS) and the SK Hep parent line (B). In order to compare transport values
between cluster plates, NS controls for each parent line were set to a value of 1 and all other transport values were
mathematically adjusted to reflect this change. Data are the average of at least four separate determinations ± SD. Asterisks
(*) denote values that are statistically significant with a P value < 0.05.
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According to the current model for the ASCT2 and LAT1 transport mechanism, these
two transporters function cooperatively as obligatory amino acid exchangers (please refer back to
Figure 1 in the INTRODUCTION section)(Fuchs and Bode, 2005; Nicklin et al., 2009). Briefly,
ASCT2 exchanges small, neutral intracellular amino acids for the uptake of extracellular
glutamine which is then used as an intracellular substrate by LAT1 to exchange for extracellular
essential amino acids, and this mechanism ultimately sustains downstream metabolic demands
and signaling to mTORC1. Due to this cooperative mechanism of transport activity, initial rate
transport analysis was performed to determine if the knockdown of one transporter would affect
the initial rate uptake activity of the other transporter (Figure 17). Initial rate glutamine uptake
was measured in HL1, HL4, SL1, and SL2, two cell lines from each of the LAT1-targeted Hep
3B and SK Hep subsets. Likewise, initial rate leucine uptake was measured in HA2, HA5, SA2,
and SA5, two cell lines from each of the ASCT2-targeted Hep 3B and SK Hep subsets. These
analyses produced mixed results, and the initial rate uptake activity of the Hep 3B-derived cell
lines was in direct opposition to the activity demonstrated by the SK Hep-derived cell lines. In
the Hep 3B set, initial rate glutamine uptake was diminished in only the HL4 cell line, and initial
rate leucine uptake was increased in HA2 and HA5 cell lines (Fig. 17A). Conversely, in the SK
Hep set, initial rate glutamine uptake rate was increased in both SL1 and SL2 cell lines, and
initial rate leucine uptake was diminished in both SA2 and SA5 cell lines (Fig. 17B). Altogether,
reductions in LAT1 or ASCT2 activity had opposing effects in the Hep 3B and SK Hep sets of
cell lines. However, while statistically significant, these changes in initial rate uptake were not
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exceptionally large changes. These results may suggest a difference in the functional relationship
between these transporters in two contexts, epithelial versus mesenchymal types of cell lines.

Figure 17. Reciprocal Na+-dependent glutamine (L-[3H]Gln) and leucine (L-[3H]Leu) initial rate uptake. Transport of
10 μM L-glutamine and 10 μM L-leucine was measured as described in MATERIALS AND METHODS. Na+-dependent Lglutamine uptake was measured in two Hep 3B-derived LAT1 knockdown cell lines (HL1 and HL4) and the non-silencing
control cell line (HNS), and L-leucine uptake was measured in two Hep 3B-derived ASCT2 knockdown cell lines (HA2 and
HA5) and the non-silencing control cell line (HNS) (A). Similarly, Na+-dependent L-glutamine uptake was measured in two
SK Hep-derived LAT1 knockdown cell lines (SL1 and SL2) and the non-silencing control cell line (SNS), and L-leucine
uptake was also measured in two SK Hep-derived ASCT2 knockdown cell lines (SA2 and SA5) and the non-silencing
control cell line (SNS) (B). Due to complementary nature of ASCT2 and LAT1 transport activity, this experiment was
performed in order to determine if knockdown of one transporter would affect the initial rate uptake activity of the other
transporter. In order to compare transport values between cluster plates, NS controls for each parent line were set to a value
of 1 and all other transport values were mathematically adjusted to reflect this change. Data are the average of at least four
separate determinations ± SD. Asterisks (*) denote values that are statistically significant with a P value < 0.05.
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Growth, mTORC1 Signaling, and Compensatory Expression

In order to measure changes in proliferative rates due to shRNA-mediated ASCT2 and
LAT1 knockdown, two types of growth asessment were performed: methylthiazol tetrazolium
(MTT) analysis and image-based automated cytometry. These two complimentary approaches
were taken due to the nature of MTT analysis. MTT analysis is a spectrophotometric assay that
measures a population of cells’ capacity to reduce a soluble yellow tetrazolium salt to an
insoluble purple formazan product, and this action is performed by mitochondrial reductase
enzymes (Berridge, Herst, and Tan, 2005). In other words, an MTT assay is an indirect
assessment of cell number based on mitochondiral activity. This approach may be undermined if
cellular mitochondrial activity is variable between the transfected cell lines, which could
conceptually occur if a reduction in ASCT2 and LAT1 transporter expression has an effect on
downstream cellular metabolism. In order to account for this possibility MTT measurements
were corroborated with direct cell count measurements using the image-based cytometric
approach.
The results of the MTT analysis and image-based automated cytometry revealed
statistically significant but overall minor changes in the proliferative rate in both the Hep 3B and
SK Hep sets of transporter targeted cell lines (Figures 18 and 19). The knockdown of ASCT2
and LAT1 transporter expression as well as corresponding reductions in amino acid initial rate
uptake, together was not sufficient to extensively affect cellular proliferation. Overall, the results
from the MTT and automated cytometric approaches were in agreement, and so MTT analysis
was selected for the remainder of growth analyses within this study.
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Figure 18. Growth in the shRNA-mediated knockdown Hep 3B and SK Hep cell lines. Growth was indirectly
measured using an MTT assay as described in MATERIALS AND METHODS. In the first graph, Hep 3B-derived
ASCT2 and LAT1 knockdown cell lines (HA2, HA5, HL1, and HL4) are shown respective to the non-silencing
control cell line (HNS) and the Hep 3B parent line (A), and in the second graph SK Hep-derived ASCT2 and LAT1
knockdown cell lines (SA2, SA5, SL1, and SL2) are shown respective to the non-silencing control cell line (SNS)
and the SK Hep parent line (B).
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Figure 19. Cellular proliferation in the shRNA-mediated ASCT2- and LAT1-knockdown Hep 3B and SK Hep
cell lines. Cellular proliferation was measured using a Tali® Image cytometer as described in MATERIALS AND
METHODS. In the first graph, Hep 3B-derived ASCT2 and LAT1 knockdown cell lines (HA2, HA5, HL1, and HL4)
are shown respective to the non-silencing control cell line (HNS) and the Hep 3B parent line (A), and in the second
graph SK Hep-derived ASCT2 and LAT1 knockdown cell lines (SA2, SA5, SL1, and SL2) are shown respective to the
non-silencing control cell line (SNS) and the SK Hep parent line (B).
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Cellular growth is fundamentally controlled through the integration of extracellular
nutrient and growth factor signals, and an essential component of this signaling cascade is the
mammalian target-of-rapamycin complex 1 (mTORC1) serine threonine kinase (Wullschleger et
al., 2006). When active, mTORC1 is phosphorylated and functions to activate cap-dependent
protein translation and inhibit autophagy by phosphorylating numerous downstream targets,
including 70 kDa ribosomal protein S6 kinase (p70 S6K), eukaryotic initiation factor 4E (eIF4E) binding protein (4E-BP1), and unc-51 like autophagy activating kinase 1/2 (ULK1/2) (please
refer back to Figure 2 in the INTRODUCTION section). To characterize mTORC1-mediated
growth signaling in the Hep 3B and SK Hep transporter suppressed cell lines, western blot
analysis was performed to evaluate the phosphorylation states of two mTORC1 targets: 4E-BP1
and p70S6K. This assessment of mTORC1 activity was implemented under controlled conditions
of growth factor stimulation, amino acid availability, and rapamycin treatment (please refer back
to Figure 9 from the mTORC1 Analysis subsection of Materials and Methods).
On the phosphorylation-specific western blots shown herein, the chemiluminescent bands
for 4E-BP1 have a characteristic stacked appearance, and this is because 4E-BP1 can exist in a
several different phosphorylation states. The top-most band in each 4E-BP1 stack represents the
heaviest state, in which 4E-BP1 has the maximum load of phosphate groups, and each band
below the top-most band represents consecutively reduced phosphorylation states. Briefly, only
fully phosphorylated 4E-BP1 is capable of dissociating from eIF-4E, and this dissociation allows
eIF-4E to participate in ribosomal recruitment and the assembly of a 5'-cap complex around
mRNAs during cap-dependent protein translation (Sonenberg, Rupprecht, Hecht, and Shatkin,
1979; Svitkin et al., 2005). The western blots in this study used an antibody probe with
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specificity to 4E-BP1 phosphorylated on threonine 37 and 46 (p-4E-BP1T37/46), and these two
phosphorylations are added to the 4E-BP1 protein directly by mTORC1 kinase activity. These
phosphorylations are responsible for priming 4E-BP1 for subsequent phosphorylations by other
cellular kinases (Gingras et al., 1999). Therefore, all of the chemiluminescent bands in the 4EBP1 stack that hybridize with p-4E-BP1T37/46 antibody are indicative of mTORC1 activity, but
only the top-most bands in each stack respresent a strong signal to cap-dependent translation
from the mTORC1 growth pathway.
The p-p70S6KT389 antibody implemented herein is also specific to a phosphorylation
performed by mTORC1 (Pullen and Thomas, 1997). The phosphorylation on threonine 389 is
responsible for priming p70S6K for further phosphorylation by phosphoinositide-dependent
kinase-1 (PDK1), ultimately activating p70S6K’s kinase activity and subsequent phosphorylation
of the S6 ribosomal protein, a step that promotes cap-dependent protein translation.
First, when the cells were treated with standard growth conditions (supplemented with
growth factors from fetal bovine serum (FBS) and normal physiological concentrations of
essential and non-essential amino acids), the level of 4E-BP1 and p70S6K phosphorylation did
not differ between the ASCT2- and LAT1-targeted cell lines relative to their respective nonsilencing (NS) and parent cell line controls (Fig. 20A, p-4E-BP1T37/46 and p-p70S6KT389).
However, the highest level of 4E-BP1 phosphorylation across the SK Hep-derived set of cell
lines was notably more robust than that of the Hep 3B-derived set of cell lines (Fig. 20A, p-4EBP1T37/46). SK Hep is a more aggressive cell line then Hep 3B, and a heightened level of 4E-BP1
phosphorylation and, therefore, more energetic growth signaling, in SK Hep is consistent with
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this cell line’s phenotype. When serum-derived growth factor signaling was removed for 18-22
hours, the Hep 3B cell lines were more sensitive to this change overall than the SK Hep cell
lines, as can be seen by a more noTable drop in the level of phosphorylation of 4E-BP1 (Fig.
20B, p-4E-BP1T37/46).

Figure 20. The influence of growth factor signaling on 4E-BP1 and p70S6K phosphorylation in the shRNA-mediated
knockdown Hep 3B and SK Hep cell lines. The phosphorylation state of 4E-BP1 and p70S6K was measured by western blot
analysis as described in MATERIALS AND METHODS. In order to control for loading, the chemiluminescent bands exposed
for each target (total 4E-BP1 and p70S6K; phospho-4E-BP1 and p70S6K) are paired to β-actin protein detected on the same
blots, respectively. The last lane of each blot (+Control) is a positive control containing cellular lysate from MCF7 cells treated
with insulin. The first array of western blots are cell lysates from Hep 3B- and SK Hep-derived cell lines treated under normal
conditions, exposed to both growth factor signaling via FBS and physiological concentrations of amino acids (A). The second
array of western blots are cell lysates from Hep 3B- and SK Hep-derived cell lines deprived of growth factor signaling (-FBS)
for 18-22 hr (overnight) (B).
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After these cell lines had been deprived of growth factor signaling for 18-22 hrs,
extracellular amino acid availability was additionally removed by incubating the cell lines in
amino acid-free sodium Krebs-Ringer bicarbonate buffer (NaKRB) for three hours (Fig. 21A).
After this incubation, the highest band of 4E-BP1 phosphorylation was no longer visible for all
of the cell lines, and phosphorylated p70S6K was undetecTable (Fig. 21A, p-4E-BP1T37/46 and pp70S6KT389). Restoration of partial amino acid signaling (normal physiological concentrations of
essential amino acids and conditionally essential glutamine) for 1 hour stimulated the
reemergance of the middle level 4E-BP1 phosphorylation bands across the Hep 3B-derived cell
lines and the top-most 4E-BP1 phosphorylation bands across the SK Hep-derived cell lines (Fig.
21B, p-4E-BP1T37/46 and p-p70S6KT389). In addition, the LAT1-targeted SL1 and SL2 SK Hep
cell lines demonstrated a subtle return of p70S6K phosphorylation (Fig. 21B, p-p70S6KT389).
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Figure 21. The influence of growth factor and amino acid deprivation followed by replenishment with essential amino
acids and glutamine on 4E-BP1 and p70S6K phosphorylation in the shRNA-mediated knockdown Hep 3B and SK Hep
cell line. The phosphorylation state of 4E-BP1 and p70S6K was measured by western blot analysis as described in MATERIALS
AND METHODS. In order to control for loading, the chemiluminescent bands exposed for each target (total 4E-BP1 and
p70S6K; phospho-4E-BP1 and p70S6K) are paired to β-actin protein detected on the same blots, respectively. The last lane of
each blot (+Control) is a positive control containing cellular lysate from MCF7 cells treated with insulin. The first array of
western blots are cell lysates from Hep 3B- and SK Hep-derived cell lines deprived of growth factor signaling (-FBS) for 18-22
hr (overnight) and then starved for amino acids in a Na+KRP buffer for 3 hours (A). The second array of western blots are cell
lysates from Hep 3B- and SK Hep-derived cell lines exposed to the same FBS and amino acid starvation conditions as the first
set, but then subsequently exposed to essential amino acids and glutamine at normal physiological concentrations for 1 hr (B).
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One hour treatment with either glutaminyl-para-nitroanilide (GPNA), an ASCT2
transport inhibitor, or 2-amino-2-norbornanecarboxlic acid (BCH), a LAT1 transport inhibitor,
did not lead to differential affects on 4E-BP1 phosphorylation between cell lines (Fig. 22A and
22B, p-4E-BP1T37/46). However, treatment with BCH appeared to increase p70S6K
phosphorylation in two of the Hep 3B-derived cell lines: HA5 and HL1 (Fig. 22B, pp70S6KT389).

Figure 22. The influence of treatment with 1 mM GPNA and 5 mM BCH in the presence of essential amino acids and
glutamine on 4E-BP1 and p70S6K phosphorylation in the shRNA-mediated knockdown Hep 3B and SK Hep cell lines.
The phosphorylation state of 4E-BP1 and p70S6K was measured by western blot analysis as described in MATERIALS AND
METHODS. In order to control for loading, the chemiluminescent bands exposed for each target (total 4E-BP1 and p70S6K;
phospho-4E-BP1 and p70S6K) are paired to β-actin protein detected on the same blots, respectively. The last lane of each blot
(+Control) is a positive control containing cellular lysate from MCF7 cells treated with insulin. The first array of western blots
are cell lysates from Hep 3B- and SK Hep-derived cell lines treated with all essential amino acids and glutamine at normal
physiological concentrations plus 1 mM glutaminyl-para-nitroanilide (GPNA), an ASCT2-specific inhibitor, for 1 hr (A). The
second array of western blots are cell lysates from Hep 3B- and SK Hep-derived cell lines treated with all essential amino acids
and glutamine at normal physiological concentrations plus 5 mM 2-amino-2-norbornanecarboxlic acid (BCH), a system L
inhibitor-specific inhibitor, for 1 hr (B).
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One hour treatment with rapamycin, an mTORC1-specific inhibitor, served as a positive
control for mTORC1 suppression and point of reference for the other treatments evaluated in the
preceding Figures 20-23. The reductions in 4E-BP1 and p70S6K phosphorylation across all of
the cell lines in response to rapamycin are very similar to the reductions that resulted from the
removal of both growth factors and amino acids (Fig. 21A vs. 23A; p-4E-BP1T37/46 and pp70S6KT389).

Figure 23. The influence of treatment with either 20 nM rapamycin or EtOH vehicle control in the presence of essential
amino acids and glutamine on 4E-BP1 and p70S6K phosphorylation in the shRNA-mediated knockdown Hep 3B and SK
Hep cell lines. The phosphorylation state of 4E-BP1 and p70S6K was measured by western blot analysis as described in
MATERIALS AND METHODS. In order to control for loading, the chemiluminescent bands exposed for each target (total 4EBP1 and p70S6K; phospho-4E-BP1 and p70S6K) are paired to β-actin protein detected on the same blots, respectively. The last
lane of each blot (+Control) is a positive control containing cellular lysate from MCF7 cells treated with insulin. The first array
of western blots are cell lysates from Hep 3B- and SK Hep-derived cell lines treated with all essential amino acids and glutamine
at normal physiological concentrations plus 20 nM rapamycin, a mTORC1-specific inhibitor, for 1 hr (A). The second array of
western blots are cell lysates from Hep 3B- and SK Hep-derived cell lines treated with all essential amino acids and glutamine at
normal physiological concentrations plus an EtOH vehicle control for 1 hr (B).
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Overall, the ASCT2- and LAT1-targeted Hep 3B and SK Hep cell lines did not
demonstrate abberrent mTORC1 activity or unique nutrient sensitivities respective to their nonsilencing and parent control cell lines, and this result is supportive of the sustained growth rate
demonstrated by the sTable transporter suppressed cell lines.
Furthermore, RT-qPCR analysis did not show a compensatory upregulation of alanineserine-cysteine transporter 1 (ASCT1 ) transporter mRNA expression in any of the ASCT2- or
LAT1-targeted cell lines (Fig. 24 A and B). Sodium-dependent neutral amino acid transporter 2
(SNAT2) and glutamine synthetase (GLUL) mRNA expression were also not substantially
changed relative to non-silencing and parent cell lines (Fig. 24 C, D, E and F, respectively). The
expression of large neutral amino acid transporter 2 (LAT2) mRNA was also analyzed via RTqPCR, but LAT2 mRNA was undecTable in both Hep 3B and SK Hep as well as their derivative
cell lines (not shown). Interestingly, in the SK Hep set of cell lines, ASCT2-targeted SA2 and
LAT1-targeted SL1, the two cell lines with the greatest degree of ASCT2 and LAT1 reduction
respectively, both demonstrated a four-fold increase in cystine-glutamate transporter (xCT)
mRNA expression (Fig. 24H).
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Figure 24. ASCT1, SNAT2, GLUL, and xCT mRNA expression in the shRNA-mediated knockdown Hep 3B and SK
Hep cell lines. mRNA expression was measured by quantitative RT-PCR analysis as described in MATERIALS AND
METHODS. Each target mRNA expression level is represented as a geometric mean of three experimental RT-qPCR runs
relative to the expression level of both TBP and HMBS housekeeping genes (HKG). The left-hand column of graphs illustrates
target mRNA expression in the shRNA-mediated knockdown Hep 3B cell lines (A, C, E, and G), and the right-hand column of
graphs illustrates target mRNA expression in the shRNA-mediated knockdown SK Hep cell lines (B, D, F, and H). mRNA
expression of ASCT1 (A and B), SNAT2 (C and D), GLUL (E and F), and xCT (G and H) is shown in the ASCT2-targeted
cell lines (HA2 and SA2) and LAT1-targeted cell lines (HL1 and SL1) in comparison to their respective non-silencing control
cell lines (HNS and SNS) and parent Hep 3B and SK Hep cell lines.
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In unpublished work antecedent to this study, it was observed that HCC cells grown in
culture without a supplementation of cystine, the dimerized form of the amino acid cysteine,
have an increased initial rate uptake of glutamine mediated by the ASCT2 transporter, and the
underlying mechanism of this response is currently unknown. The preceding RT-qPCR analysis
revealed an increased mRNA expression for cystine-glutamate transporter (xCT) in two SK Hepderived cell lines, SA2 and SL1. Functionally, xCT is an antiporter that exchanges intracellular
L-glutamate for extracellular L-cystine, and, like the LAT1 transporter, the xCT transporter is a
heterodimeric complex between the xCT light chain and the glycosylated heavy subunit 4F2
heavy chain (4F2hc/CD98) (Lewerenz, Maher, and Methner, 2012). With this in mind, the
following experiment was designed to answer two questions: (1) does an increase in xCT
transporter expression lead to an enhanced sensitivity to cystine starvation, and (2) how would
the consequential increase in initial rate glutamine uptake manifest if the cystine starved cells
were no longer able to recruit ASCT2 to mediate glutamine uptake, such as ASCT2-targeted Hep
3B and SK Hep cells?
Initial rate glutamine transport analysis was performed on the ASCT2- and LAT1targeted Hep 3B and SK Hep cell lines after cystine (CYS) starvation for 14 hours (Fig. 25 A and
B, respectively). In this Figure, the three treatment conditions were as follows: the control, cells
that were not subjected to CYS starvation (dark grey), CYS starved cells (medium grey), and
CYS starved cells that were exposed to a system A glutamine transport inhibitor, 2methylaminoisobutyric acid (MeAIB) when initial rate glutamine measurements were performed
(light grey). In the third treatment condition, MeAIB was included in the uptake mixture to
differentiate between system A and system ASC-mediated glutamine transport.
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Figure 25. Na+-dependent glutamine (L-[3H]Gln) uptake in the shRNA-mediated knockdown Hep 3B and SK Hep
cell lines after 14 hr cystine-starvation. Transport of 10 μM L-glutamine was measured as described in MATERIALS
AND METHODS. For a 14 hr time period, each cell line was either given normal growth media or media without cystine,
and subsequent L-glutamine uptake was performed in the presence or absence of 5 mM 2-methylaminoisobutyric acid
(MeAIB), a system A transporter inhibitor. Na+-dependent L-glutamine uptake was measured in the ASCT2-targeted Hep
3B cell line (HA2) and LAT1-targeted Hep 3B cell line (HL1) in comparison to the non-silencing control cell line (HNS)
and the parent Hep 3B cell line (A). Similarly, Na+-dependent L-glutamine uptake was measured in the ASCT2-targeted
SK Hep cell line (SA2) and LAT1-targeted SK Hep cell line (SL1) in comparison to the non-silencing control cell line
(SNS) and the parent SK Hep cell line (B). Data are the average of at least four separate determinations ± SD. Asterisks
(*) denote values that are statistically significant with a P value < 0.05.
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Following the cystine starvation period, initial rate glutamine uptake was significantly
increased all of the cell lines except for the SA2 and SL1 SK Hep cell lines, the two cell lines
with significantly increased levels of xCT mRNA according to earlier RT-qPCR analysis (Fig.
25B). These results indicate that increased xCT transporter expression does not impart a greater
sensitivity to this specific CYS starvation response. In the ASCT2-targeted Hep 3B cells, the
increased initial rate glutamine uptake following CYS starvation was not mediated by system A
glutamine transporters (insensitive to MeAIB inhibition), which indicates that the enhanced
glutamine uptake response is mediated by either system ASC glutamine transporters, residual
ASCT2 expression despite ASCT2-targeted shRNA expression in this cell line, or system N
glutamine transporters, SNAT3 or SNAT5 (Fig. 25A). These results may also be evidence that
the ASCT2 and LAT1 transporters are necessary to the mechanism that mediates increased initial
rate glutamine uptake in response to CYS starvation in SK Hep, but not in Hep 3B, and
therefore, these transporters may be more responsible for adaptive amino acid-based responses in
mesenchymal type HCC, than epithelial type HCC.

Drug Treatments

MTT assays were performed to assess the effects of four different drug treatments on the
proliferative rates of ASCT2- and LAT1-targeted Hep 3B and SK Hep cell lines, respective to
their non-silencing and parent cell lines. In the following Figures 26 and 27, all untreated cells
are represented with solid lines and all treated cells are represented with dashed lines.
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Figure 26. Drug treatment and growth in the shRNA-mediated knockdown Hep 3B cell lines. Growth was
indirectly measured using MTT analysis as described in MATERIALS AND METHODS. MTT assays were
performed at 48 and 72 hour time points after treatment with each of the following: (A) WZB117 (10 μM), glucose
transporter type 1 (GLUT1) inhibitor; (B) sorafenib (10 μM), an FDA approved tyrosine kinase inhibitor used in
the treatment of liver, kidney, and thyroid cancers; (C) metformin (10 mM), an FDA approved antidiabetic
treatment; (D) methionine sulfoximine (MSO)(1.5 mM), a glutamine synthetase inhibitor; and (E) EtOH vehicle
control. Data from each treatment has been graphed against the results from MTT analysis on untreated cells.
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Figure 27. Drug treatment and growth in the shRNA-mediated knockdown SK Hep cell lines. Growth was
indirectly measured using MTT analysis as described in MATERIALS AND METHODS. MTT assays were performed
at 48 and 72 hour time points after treatment with each of the following: (A) WZB117 (10 μM), glucose transporter
type 1 (GLUT1) inhibitor; (B) sorafenib (10 μM), an FDA approved tyrosine kinase inhibitor used in the treatment of
liver, kidney, and thyroid cancers; (C) metformin (10 mM), an FDA approved antidiabetic treatment; (D) methionine
sulfoximine (MSO)(1.5 mM), a glutamine synthetase inhibitor; and (E) EtOH vehicle control. Data from each
treatment has been graphed against the results from MTT analysis on untreated cells.
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WZB117, a small molecular inhibitor of glucose transporter type 1 (GLUT1) is a drug
that has been shown to downregulate glycolysis, induce cell-cycle arrest, and inhibit cancer cell
growth in human non–small cell lung cancer and breast ductal carcinoma cell lines (Y. Liu et al.,
2012). WZB117 did not significantly affect growth in either of the Hep 3B or SK Hep sets of cell
lines (Fig. 26A and 27A).
Sorafenib is an FDA approved drug which acts as an anti-angiogenic tyrosine kinase
inhibitor and an anti-proliferative Raf serine threonine kinase inhibitor, and sorafenib is currently
used in the treatment of liver, kidney, and thyroid cancers (Fishman, Tomshine, Fulp, and
Foreman, 2015; Keating and Santoro, 2009; Thomas et al., 2014). Sorafenib had a considerable
negative impact on all of the treated cell lines, though the effects of sorafenib were not
discriminatory between ASCT2 and LAT1 transporter suppressed cell lines as compared to their
non-silencing and parent cell lines (Fig. 26B and 27B).
Another FDA approved drug called metformin is currently prescribed as an antidiabetic
treatment, but it has recently caught the attention cancer research community due to early
observational data that suggests that metformin may lower the risk of breast and colorectal
cancers, amongst others (Kasznicki, Sliwinska, and Drzewoski, 2014). At the present time, the
precise anti-cancer mechanism of metformin is unknown, but the majority of competing theories
agree that metformin has an inhibitory action on the mTORC1 pathway. In this drug treatment
series, metformin was not as effective at suppressing growth as sorafenib. Though, metformin
was more successful in inhibiting growth in the Hep 3B set of cell lines compared to the SK Hep
set of cell lines (Fig. 26C vs. 27C). NoTable cell lines that exhibited a significant susceptibility
to metformin treatment were the ASCT2-targeted HA5 Hep 3B cell line and ASCT2-targeted
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SA2 SK Hep cell line. However, it is unclear if this adverse effect on growth is attribuTable to
the reduction of ASCT2 in these two cell lines because the HA2 cell line from the Hep 3B set
and the SA5 cell line from the SK Hep set did not demonstrate the same negative reactions to
metformin treatment.
Methionine sulfoximine (MSO) is a glutamine synthetase inhibitor which has been used
previously to test intracellular glutamine biosynthetic vulnerabilities in HCC cell lines (Tardito et
al., 2011). MSO treatment had no effect on growth in any of the cell lines in either Hep 3B or SK
Hep cell line sets (Fig. 26D and 27D).

Acridine Orange Staining and Autophagy

From each parent cell line subset, the two cell lines that demonstrated the best reductions
in ASCT2 protein (HA2 and SA2) and two cell lines that demonstrated the best reductions in
LAT1 protein (HL1 and SL1), as determined by western blot analysis, were selected along with
their respective non-silencing control and parent cell lines (HNS, Hep 3B, SNS, and SK Hep) for
a visual evaluation using an acridine orange (AO) dual fluorescence stain. When exposed to blue
light (excitation: 458 nm), AO that is bound to RNA and indiscriminate acidic cellular
compartments, such as lysosomes, endosomes, and autophagosomes, will emit an orange-red
fluorescence (590–660 nm), and AO that is bound to DNA will emit a green fluorescence (480–
560 nm) (Pierzynska-Mach, Janowski, and Dobrucki, 2014). In this preliminary assessment, the
objective was to determine if amino acid transporter suppressed cells generally exhibited a
greater amount of red fluorescent punctate staining of cytoplasmic compartments as compared to
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their non-silencing and parent line controls. As previously stated, AO binding does not
differentiate between functionally different types of intracellular acidic compartments, but this
assessment was used as an early look at potential autophagosome prevalence in these cells. In the
Hep 3B set of cell lines, red cytoplasmic staining was not considerably different, though the
LAT1-targeted HL1 cell line appeared to have more red punctate bodies in general (Figure 28).
In the SK Hep set of cell lines, the non-silencing SNS cell line and the ASCT2-targeted SA2 cell
line exhibited red punctate staining than was more condensed in appearance than the SK Hep
parent cell line and the LAT1-targeted SL1 cell line (Figure 29). Overall, the differences
observed in these two sets of cell lines were minimal, and this assessment would have to be
repeated many more times before definite conclusions could be drawn about any change in acidic
vacuolar organelles between these cell lines.
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Figure 28. Acridine orange stain in the shRNA-mediated knockdown Hep 3B cell lines. For a preliminary
qualitative assessment of the autophagic activity in the stably transfected cell lines, an acridine orange (AO) applied.
The upper, left-hand quandrant of each frame is the red fluorescence (590 nm) emitted when AO is bound to RNA and
small acidic compartments, such as lysosomes, endosomes, and autophagosomes. The upper, right-hand quadrant of
each frame is the green fluorescence (525 nm) emitted when AO is bound to DNA. The lower, left-hand quadrant of
each frame is an image produced using a differential interference contrast (DIC) filter, and the final overlay image of all
three filter sets is the lower, right-hand quadrant of each frame. All images were taken with a Zeiss LSM PASCAL
confocal laser scanning microscope with a FITC-Rhodamine excitation/dichroic/emitter filter (LP560; BP 505-530).
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Figure 29. Acridine orange stain in the shRNA-mediated knockdown SK Hep cell lines. For a preliminary
qualitative assessment of the autophagic activity in the stably transfected cell lines, an acridine orange (AO)
applied. The upper, left-hand quandrant of each frame is the red fluorescence (590 nm) emitted when AO is bound
to RNA and small acidic compartments, such as lysosomes, endosomes, and autophagosomes. The upper, righthand quadrant of each frame is the green fluorescence (525 nm) emitted when AO is bound to DNA. The lower,
left-hand quadrant of each frame is an image produced using a differential interference contrast (DIC) filter, and the
final overlay image of all three filter sets is the lower, right-hand quadrant of each frame. All images were taken
with a Zeiss LSM PASCAL confocal laser scanning microscope with a FITC-Rhodamine
excitation/dichroic/emitter filter (LP560; BP 505-530).
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In response to decreased initial rate uptake of amino acids resultant from shRNAmediated transporter suppression, cells can potentially supplement cytoplasmic amino acid
availability through an increased rate of internal protein turnover and one way protein turnover
may be influenced is through increased autophagy. As discussed earlier, active mTORC1 is able
to contribute to the suppression of autophagy by phosphorylating Unc-51-like autophagy
activating kinase 1 (ULK1) (please refer back to Figure 2 in the INTRODUCTION section). The
mTORC1-mediated phosphorylation of serine 757 (S757) on ULK1 prevents the interaction
between adenosine monophosphate-activated protein kinase (AMPK) and ULK1, thereby
preventing AMPK from phosphorylating ULK1 to activate its function in promoting early
phagophore formation in autophagy (Kim et al., 2011). Western blots were performed to
evaluate the phosphorylation of ULK1 on S757 in response to growth factor signaling (FBS
supplementation), extracellular amino acid availability, and chemical treatments with 2-amino-2norbornanecarboxlic acid (BCH), a system L-specific transport inhibitor, and glutaminyl-paranitroanilide (GPNA), a system ASC-specific transport inhibitor (Figure 30).
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Figure 30. The influence of serum, amino acid supplementation, and inhibitory treatments with BCH or GPNA on
ULK-1 phosphorylation in the shRNA-mediated knockdown Hep 3B and SK Hep cell lines. The phosphorylation
state of Unc-51-like autophagy activating kinase 1 (ULK-1) was measured by western blot analysis as described in
MATERIALS AND METHODS. In order to control for loading, the chemiluminescent bands exposed for each target
(total ULK-1 and p-ULK-1) are paired to β-actin protein detected on the same blots, respectively. Four comparisons are
represented here (A-D): (A) normal growth medium (+FBS/+EAA) versus growth medium without serum-derived
growth factor stimulation (-FBS/+AA); (B) growth medium without both serum-derived growth factor and amino acid
stimulation (-FBS/-AA) versus that same starvation medium supplemented with only glutamine as normal physiological
concentrations (-FBS/-AA/+GLN); (C) growth medium with only essential amino acid supplementation (-FBS/+EAA/GLN) versus growth medium with both essential amino acid and glutamine supplementation (-FBS/+EAA/+GLN); and
(D) growth medium with both essential amino acid and glutamine supplementation and containing either 5 mM 2-amino2-norbornanecarboxlic acid (BCH), a system L inhibitor-specific inhibitor, or 1 mM glutaminyl-para-nitroanilide
(GPNA), an ASCT2-specific inhibitor. The duration of all treatments was 1 hr before cell lysis. The ULK-1
phosphorylation state was measured in the Hep 3B-derived ASCT2-targeted (HA2) and LAT1-targeted (HL1) cell lines
in comparison to the non-silencing control cell line (HNS). Similarly, the ULK-1 phosphorylation state was measured in
the SK Hep-derived ASCT2-targeted (SA2) and LAT1-targeted (SL1) cell lines in comparison to the non-silencing
control cell line (SNS).
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Overall, S757 ULK1 phosphorylation was more robust in all of the SK Hep-derived cell
lines (SNS, SA2, and SL1), in comparison to the Hep 3B-derived set of cell lines (HNS, HA2,
and HL1), and this result is complimentary to the amplified mTORC1 activity demonstrated by
SK Hep in the preceding 4E-BP1 phosphorylation western blot assessment (Fig. 20A; p-4EBP1T37/46). Another general observation that can be made here is that overall expression of ULK1
as well as the phosphorylation S757 on ULK1 in the LAT1-targeted HL1 cell line was
diminished overall compared to the non-silencing control HNS cell line (Figure 30). This may be
evidence that shRNA-mediated LAT1 suppression in Hep 3B reduces mTORC1-mediated
suppression of autophagy through ULK1 phosphorylation. Interestingly, this was the same cell
line that exhibited slightly more cytoplasmic red punctate bodies when stained with acridine
orange, a complementary observation to lowered S757 ULK1 phosphorylation (Figure 28). S757
ULK-1 phosphorylation in the ASCT2-targeted HA2 cell line was reduced when growth factor
stimulation was removed, but overall expression of the ULK1 protein in this treatment was also
reduced (Fig 30A; p-ULK1S757).
In the absence of growth factor stimulation and extracellular amino acid availability,
subsequent replenishment with either glutamine or essential amino acids alone did not affect
S757 ULK1 phosphorylation in any of the cell lines (Fig. 30B; p-ULK1S757). However,
replenishment with both glutamine and essential amino acids had a synergistic effect and
promoted S757 ULK1 phosphorylation in three of the cell lines: non-silencing HNS and ASCT2targeted HA2 derived from Hep 3B and non-silencing SNS derived from SK Hep (Fig. 30C; pULK1S757). This result could be evidence that the shRNA-mediated suppression of ASCT2 or
LAT1 is disruptive to mTORC1-mediated suppression of autophagy in the presence of both
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extracellular essential amino acids and glutamine. Though with this result in mind, BCH and
GPNA transport inhibitor treatments failed to affect S757 ULK-1 phosphorylation in all of the
cell lines, and so the mechanism of mTORC1 mediated phosphorylation of ULK1 may be
independent of LAT1 and ASCT2 transport activity upstream in this pathway (Fig. 30D; pULK1S757).
In order to compare mTORC1-mediated phosphorylation between two mTORC1 targets,
4E-BP1 and ULK1, western blot analysis was performed on cells treated with rapamycin, an
mTORC1-specific inhibitor (Figure 31). In the Hep 3B-derived set of cell lines, rapamycin
treatment only negatively affected S757 ULK1 phosphorylation in the non-silencing HNS and
ASCT2-targeted HA2 cell lines, with no effect on the LAT1-targeted HL1 cell line (Figure 31; pULK1S757). Furthermore, rapamycin treatment of the SK Hep-derived set of cell lines had no
effect on S757 ULK1 phosphorylation. This result may indicate that phosphorylation of ULK1 at
S757 could be mediated by another currently unknown serine kinase. Rapamycin treatment
suppressed T37/46 phosphorylation of 4E-BP1 equally across all of the cell lines (Figure 31; p4E-BP1T37/46). This initial analysis of mTORC1-mediated signaling to autophagy did not reveal
outstanding differences between transporter-suppressed cells and their respective parent cell line
controls. The serine threonine kinase activity of mTORC1 was determined to be more robust in
SK Hep relative to Hep 3B, and there is evidence that the LAT1 transporter may participate in
promoting mTORC1-mediated suppression of autophagy in Hep 3B, but not in SK Hep.
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Figure 31. The influence of treatment with either 20 nM rapamycin or EtOH vehicle control on 4E-BP1 and ULK-1
phosphorylation in the shRNA-mediated knockdown Hep 3B and SK Hep cell lines. The phosphorylation state of ULK-1
and 4E-BP1 was measured by western blot analysis as described in MATERIALS AND METHODS. In order to control for
loading, the chemiluminescent bands exposed for each target (total ULK-1, p-ULK-1, 4E-BP1, and p-4E-BP1) are paired to
β-actin protein detected on the same blots, respectively. All cell lines were treated with growth medium containing both
essential amino acids and glutamine with either a treatment of 20 nM rapamycin, an mTORC1 inhibitor, or an ethanol vehicle
control (EtOH). The duration of all treatments was 1 hr before cell lysis. Hep 3B-derived ASCT2-targeted (HA2) and LAT1targeted (HL1) cell lines are shown in comparison to the non-silencing control cell line (HNS). Similarly, SK Hep-derived
ASCT2-targeted (SA2) and LAT1-targeted (SL1) cell lines are shown in comparison to the non-silencing control cell line
(SNS).
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Discussion

The expression of tGFP and puromycin resistance initially confirmed positive
transfection with the GIPZ shRNAmir plasmid vectors in Hep 3B and SK Hep HCC cell lines.
Successful shRNA-mediated suppression of ASCT2 and LAT1 was demonstrated by RT-qPCR,
western blot, and initial rate uptake analysis. The A2 and L1 shRNAmir designs were the most
effective at targeting the ASCT2 and LAT1 mRNA transcripts respectively, in both cell lines.
Functionally, the effects of suppressing one transporter have small and variable effects on the
activity of the other transporter, and these effects are dependent on cell line identity.
Transporter suppressed cells demonstrated no change in proliferative rate and mTORC1mediated growth signaling relative to their non-silencing and parent cell line controls. Overall,
the extent of 4E-BP1 phosphorylation was enhanced in SK Hep when compared to Hep 3B,
demonstrating a molecular indication of enhanced growth signaling in mesenchymal type versus
epithelial type HCC. The results of the drug treatment series indicated that Hep 3B and SK Hep
are overall very susceptible to treatment with sorafenib, an FDA-approved drug currently used in
the treatment of HCC, but none of the drug treatments had any differential effects on
proliferation in the transporter suppressed cells versus their non-silencing and parent cell lines.
RT-qPCR analysis of other amino acid transporters (ASCT2, SNAT2, and LAT2) mRNA
did not show a compensatory upregulation of other transporters that could mediate glutamine and
leucine influx in the absence of ASCT2 and LAT1. Furthermore, glutamine synthetase (GLUL)
expression was also unchanged across all of the cell lines, and this is evidence that ASCT2targeted cells do not supplement diminished extracellular glutamine influx through promoting
intracellular expression of glutamine synthesis. In support of this finding, the glutamine
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synthetase-specific inhibitor methionine sulfoximine (MSO) failed to affect the proliferative rate
across these cell lines.
In addition, RT-qPCR analysis revealed an upregulation of the xCT transporter in two SK
Hep-derived cell lines, SA2 and SL1. The xCT transporter exchanges intracellular L-glutamate
for extracellular L-cystine, and L-cystine is an important substrate for glutathione biosynthesis.
Glutathione production is a protective mechanism against oxidative stress, and the expression of
xCT has also been correlated to chemotherapy and radiotherapy resistance as well as poor
clinical prognosis (Lo, Ling, Wang, and Gout, 2008). The xCT transporter has also been the
focus of several studies in liver, ovarian, and brain cancers (Kinoshita et al., 2013; Okuno et al.,
2003; Takeuchi et al., 2013). Interestingly, a study which used radiolabeled glutamine and flux
imbalance analysis in glioblastoma cells, demonstrated that there is a functional competition for
intracellular glutamate resources between xCT-mediated glutamate export and GLUL-mediated
conversion of glutamate to glutamine which fuels nucleotide biosynthesis, not TCA activity,
even under conditions of glutamine starvation (Tardito et al., 2015). In the current study, the
upregulation of xCT mRNA expression in ASCT2- and LAT1-suppressed mesenchymal type
HCC cells may indicate that transporter suppression led to increased levels of oxidative stress,
which may have triggered an intracellular demand for L-cystine for glutathione biosynthesis.
Increased xCT transporter expression did not sensitize SK Hep-derived SA2 and SL1 cell
lines to cystine starvation. Conversely, these two cell lines were not able to increase their initial
rate glutamine uptake after cystine starvation, suggesting that the ASCT2- and LAT1-targeted
SK Hep cells were no longer able to recruit ASCT2 to mediate glutamine uptake. Conceptually,
it is possible that cystine starvation leads to an increased initial rate glutamine uptake due to
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stress on the glutathione biosynthetic pathway. When extracellular cystine levels are diminished,
ASCT2-mediated import of glutamine can boost intracellular levels of glutamate by GLUL
conversion, and that glutamate can be used to exchange for extracellular cystine by the xCT
transporter.
The results of acridine orange staining and ULK1 phosphorylation specific western blot
analyses did not show outstanding differences in autophagy between the transporter suppressed
cell lines relative to the non-silencing and parent cell line controls, with the exception of the
LAT1-targeted Hep 3B cell line HL1. The HL1 cell line showed decreased ULK1 protein
expression overall and increased levels of cytoplasmic red punctate staining, which may be
evidence of an enhanced level of autophagy in response to LAT1 suppression in Hep 3B.
However, this analyses was very preliminary, and more investigation will be needed to support
this finding.
Overall, the shRNA-mediated system of ASCT2 and LAT1 suppression did not
completely eliminate the expression of either transporter, as evidenced by RT-qPCR, western
blots, and initial rate uptake analysis. This means that translating this shRNA-based system to in
vivo therapeutic design may challenging. Furthermore, the suppression of ASCT2 in particular
did not affect growth, in direct contradiction to the early antisense RNA study which found
ASCT2 suppression was sufficient to trigger cell death. In order to address the possibility that
these cell lines are maintaining a threshold level of ASCT2 and LAT1 transporter expression that
is critical to survival, a more effective system of transporter knockout needs to be implemented.
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CHAPTER 2: CRISPR-CAS9-MEDIATED KNOCKDOWN OF ASCT2 AND LAT1

Introduction

Genomic Editing with CRISPR-Cas9

The narrative of clustered regularly interspaced short palindromic repeats (CRISPR)CRISPR associated protein (Cas) discovery and characterization begins with a landmark
experiment that inadvertently revealed a novel CRISPR sequence while studying the iap gene in
Escherichia coli (Ishino, Shinagawa, Makino, Amemura, and Nakata, 1987). Due to the
advancement of sequencing technology thereafter, very similar short, repetitive palindromic
sequences were discovered within the prokaryotic genomes from distant phylogenetic groups,
and these CRISPR sequences were first classified as short regularly spaced repeats (SRSRs)
(Mojica, Diez-Villasenor, Soria, and Juez, 2000). In 2005, two major breakthroughs led to the
current understanding of the function of CRISPR sequences: (1) the sequence identity of spacer
segments in between the SRSRs matched foreign DNA from bacteriophage and conjugative
plasmid origins (Bolotin, Quinquis, Sorokin, and Ehrlich, 2005; Mojica, Diez-Villasenor, GarciaMartinez, and Soria, 2005; Pourcel, Salvignol, and Vergnaud, 2005); and (2) a prokaryotic DNA
endonuclease was hypothetically predicted which would later be identified as a Cas enzyme
(Saunders et al., 2005). These findings informed later work that established CRISPR-Cas9 as a
mechanism of adaptive immunity in prokaryotes (Barrangou et al., 2007). Bacteriophage-
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infected bacteria can integrate new spacers into their genome as a kind of molecular memory,
and then these sequences can be used to create specific guide RNA (gRNA) that enables the
recognition and destruction of foreign DNA by endogenous Cas endonuclease enzymes.
Importantly, Cas enzymes distinguish target foreign genomic transcripts from the bacterial
CRISPR locus used to produce specific gRNAs by recognizing and binding to protospacer
adjacent motifs (PAMs) in the foreign DNA, and PAMs are short recognition sequences which
are highly specific to different types of Cas enzymes (Marraffini and Sontheimer, 2010; Mojica,
Diez-Villasenor, Garcia-Martinez, and Almendros, 2009).
A variety of different CRISPR-Cas classifications have been described based on the
identity and number of the Cas enzymes involved in each nucleolytic mechanism (Wright,
Nunez, and Doudna, 2016) . The description herein will focus on type 2 CRISPR-Cas9 which
was the first type of CRISPR-Cas system to be implemented in human cells (Cong et al., 2013;
Mali et al., 2013). In order to adapt CRISPR-Cas biology to gene editing in mammalian cells,
plasmid vectors are designed which, upon transfection, can artificially introduce the expression
of a Cas9 endonuclease and a gRNA that is specific to a gene target. The regions of the human
genome that are compatible with CRISPR-Cas9 editing are dependent upon the intrinsic
distribution of human PAM sequences (5’-NGG-3’) that facilitate recognition by Cas9.
(Ramalingam, Annaluru, and Chandrasegaran, 2013). To this day, CRISPR-Cas9-based genomic
editing is a fairly new technology, but it has already vastly improved the study and
characterization of a wide array of potential therapeutic gene targets.
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Targeting ASCT2 and LAT1 with CRISPR-Cas9

The shRNA-mediated mechanism of ASCT2 and LAT transporter suppression from
Chapter 1 did not yield a complete knockout of the two transporters. In order to better understand
the necessity and function of these transporters in the biology of HCC, the CRISPR-Cas9 gene
editing system was used to introduce permanent, dysfunctional mutations to the ASCT2 and
LAT1 genes (SLC1A5 and SLC7A5I, respectively).
The specific CRISPR-Cas9 plasmid vector design (pCLIP-ALL-EFS-Puro) used for this
study is comprised of several key components (Figure 32). A polymerase III U6 promoter (in
tan) is located upstream of a customized gRNA sequence, and the activity of this promoter is
supported by an upstream cytomegalovirus (CMV) enhancer element (in blue). U6 promoters are
commonly implemented to drive the expression of small nuclear RNA and miRNA, and CMV
enhancer elements have been shown to improve the expression of some shRNA designs (Xia et
al., 2003; Zhou, Huang, and Xia, 2008). An elongation factor-1α (EFS) short promoter (in
turquoise) is located upstream of the Cas9 gene (in maroon) and the puromycin resistance gene
(PuroR) (in green), and the use of the EFS promoter has been shown to improve the expression of
very large transgenes (Holehonnur, Lella, Ho, Luong, and Ploski, 2015). The Cas9 gene is
followed by a nucleoplasmin- nuclear localization signal (NLS) (in pink), and this sequence
encodes a small peptide that acts as a signal for the import of Cas9 into the cell nucleus
(Dingwall, Robbins, Dilworth, Roberts, and Richardson, 1988). The woodchuck posttranscriptional regulatory element (WPRE) (in grey) is an enhancer element that supports the
transcription of upstream genes. A second selecTable marker, the ampicillin resistance gene
(AmpR) (in green) is used for amplification of this plasmid vector in bacterial cell culture.
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Notably, this vector does not encode any fluorescent reporter proteins, so visual assessment of
transfection efficiency is not possible.

Figure 32. Illustration of the pCLIP-All-EFS-Puro CRISPR-Cas9 plasmid vector design. transEDIT™
Lentiviral gRNA plus Cas9 (pCLIP-All) Target Gene Sets [technical manual].2015. TransOMIC Technologies inc.

The general mechanism of CRISPR-Cas9-mediated genomic editing is illustrated in
Figure 33. One important aspect of this silencing system is that, after the Cas9 endonuclease
creates a double-stranded break in the target DNA, an InDel mutation occurs, and a premature
stop codon is formed at the site of excision. This means that transcription of mutated SLC1A5
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and SLC7A5 genes is not inhibited. However, all mRNA transcripts arising from the mutated
genes are dysfunctional and transcription will fail to produce the respective transporter proteins.

Figure 33. CRISPR-Cas9 mechanism of silencing. Transfection with the CRISPR-Cas9 plasmid construct facilitates the
production of a Cas9 DNA endonuclease and a guide RNA (gRNA). Cas9 recruits the gRNA to specifically direct its gene
editing function through complementary binding between the gRNA and the target gene. A three-base long protospacer
adjacent motif (PAM) sequence must also be present downstream of the targeted gene sequence in order for Cas9 to bind.
Once bound to the target gene, Cas9 mediates a double-stranded break and an InDel mutation in which a premature stop
codon is formed at the site of excision. This mutation is followed by non-homologous end joining (NHEJ) DNA repair of the
double-stranded break. Image reproduced with reference to transEDIT™ Lentiviral gRNA plus Cas9 (pCLIP-All) Target
Gene Sets [technical manual]. 2015. TransOMIC Technologies inc.

Three custom gRNA designs were selected to target each amino acid transporter gene
(SLC1A5 and SLC7A5), and one gRNA with no sequence homology to any known mammalian
gene was selected as a CRISPR-Cas9 system control. All of the sequence information for each
gRNA design is listed in Table 2. This Table also includes the specifically targeted genomic
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location that are complimentary to the gRNA sequences as a reference. Herein, the name of each
cell line generated from successful transfection with each of these unique CRISPR-Cas9 plasmid
vectors will receive the identifications denoted on Table 1 (A1-A3; L1-L3, and NS,
respectively).

Table 2. CRISPR-Cas9 gRNA sequences and their endogenous gene target regions
gRNA sequence (no PAM) (5’-3’)
[GRCh38.p7 Primary Assembly target]

Target Gene
Symbol

CRISPR Clone ID

SLC1A5 (ASCT2) NC_000019.10
Chrom. 19: 46,759,685 – 46,788,622

Target
Type

SLC7A5 (LAT1) NC_000016.10
Chrom.16: 87,830,022 – 87,869,499
TEVH-1126600

TGGCAAACACTACCAAGCCC
[46,782,492 – 46,782,511]

Antisense

GGTCTCCTGGATCATGTGGT
[46,782,381 – 46,782,400]

Sense, intronexon boundary

CCACGATCTTGCCAGCCACC
[46,778,862 – 46,778,881]

Antisense

GATGCTGGCCGCCAAGAGCG
[87,869,329 – 87,869,348]

Sense

ATTGTGCTGGCATTATACAG
[87,841,074 – 87,841,093]

Sense

Sense

(L3)

CGGAACATCACGCTGCTCAA
[87,869,262 – 87,869,281]

Non-silencing

GGAGCGCACCATCTTCTTCA

N/A

SLC1A5
(A1)
TEVH-1193742
SLC1A5
(A2)
TEVH-1260884
SLC1A5
(A3)
TEVH-1112259
SLC7A5
(L1)
TEVH-1179401
SLC7A5
(L2)
TEVH-1246543
SLC7A5
TELA1011
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Materials and Methods

* Please note, unless stated otherwise, all materials and methods within this section are in
accordance with those outlined in the Materials and Methods section for CHAPTER 1.

Mammalian Cell Culture

The human hepatoma cell lines used in this part of the study were HUH7 and SK Hep
cells (both from American Type Culture Collection, Rockville, MD), and SK Hep-derived AS1-1
and S2-1 cells, two cell lines previously established by Fuchs and Bode, 2004.

Plasmids, Transfection, and Antibiotic Selection

The pCLIP-All-EFS-Puro CRISPR-Cas9 plasmid vectors used in this study are a product
of transOMIC technologies (Huntsville, AL). A comprehensive map of the pCLIP-All-EFS-Puro
vector plasmid vector can be found in Figure 32 of Targeting ASCT2 and LAT1 with CRISPRCas9 in the INTRODUCTION section. The three CRISPR-Cas9 sequences selected to target the
SLC1A5 gene have following clone IDs: TEVH-1126600, TEVH-1193742, and TEVH-120884,
referred to herein as A1, A2, and A3, respectively. The three CRISPR-Cas9 sequences selected
to target SLC7A5 gene have the following clone IDs: TEVH-1112259, TEVH-1179401, and
TEVH-1246543, referred to herein as L1, L2, and L3, respectively. The clone ID of the nonsilencing CRISPR-Cas9 sequence that served as a CRISPR-Cas9 silencing system control is
TELA1011. All gene target sequences can be found in Table 2 of Targeting ASCT2 and LAT1
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with CRISPR-Cas9 in the INTRODUCTION section. All pCLIP-All-EFS-Puro CRISPR-Cas9
plasmids were purchased in PrimePlus E. coli stocks (60% glycerol) and stored at -80°C.
HUH7 and SK Hep cells were transfected with pCLIP-All-EFS-Puro CRISPR-Cas9
plasmid using electroporation via the Neon® Transfection System (Thermo Scientific).
Transfections were carried out Resuspension Buffer R (a proprietary formulation), and stably
transfected cells were maintained under selective pressure in growth media supplemented with
0.5 μg/ml puromycin for SK Hep and 3.0 μg/ml for HUH7(Gibco).

Glutamine and Leucine Accumulation Analyses
Tritium labeled glutamine and leucine (L-[3H]Gln) and L-[3H]Leu) were included in
amino acid uptake mixes at a concentration of 3 μCi/ml concentration. Amino acid accumulation
was performed in DMEM (4.5 mg/ml D-glucose) supplemented with 10% triple 0.1 μm filtered
dialyzed fetal bovine serum (dFBS) and 100 μM unlabeled L-glutamine. All measurements were
carried out at 37°C and were terminated at consecutive time points (30 s, 1 min, 10 min, 30 min,
1 hr, and 1.5 hr) by three rapid washes with an ice-cold phosphate-buffered saline (PBS)
solution. Free and biosynthetically incorporated fractions of accumulated radiolabeled amino
acid were derived by an acid precipitation. At the 1.5 hr accumulation time point, the cells were
treated (0.2 ml/well) with 10% (w/v) trichloroacetic acid (TCA)(Acros, New Jersey, USA) and
held on ice for 30 minutes. Then, 0.1 ml of the supernatant, representative of the free fraction of
radiolabeled amino acid, was removed analyzed by scintillation spectrophotometry. The
remaining acid-precipitated cellular macromolecules in each well, representative of the
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incorporated fraction of radiolabeled amino acid, were washed three times with ice-cold PBS (1
ml/well/wash), solubilized by adding the standard lysis buffer (0.2 ml/well of 0.2% SDS and 0.2
N NaOH), neutralized, and analyzed by scintillation spectrophotometry as previously described.
Free radiolabeled amino acid values (free nmol AA/mg protein) were calculated as the counts per
minute (cpm) of the supernatant divided by the specific activity of the relevant amino acid
uptake mix (glutamine or leucine; cpm/nmol) and normalized to the protein concentration (mg)
of each well as determined by a bicinchoninic acid (BCA) assay. Incorporated radiolabeled
amino acid values (incorporated nmol AA/mg protein) were calculated with the same equation
except the counts per minute (cpm) in these calculations were derived from the precipitated
fraction from each well. All transport values depicted are the average ± SD of four separate
determinations.
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Results

CRISPR-Cas9-mediated ASCT2 and LAT1 Knockout

For this part of the project, the hepatoma cell line HUH7 was used in place of the Hep 3B
cell line, as representative of epithelial-type HCC. This change was made due to the difficulty of
successfully transfecting Hep 3B with the CRISPR-Cas9 plasmid vector. Transfected HUH7 and
SK Hep cell lines were grown under puromycin-selective conditions, and the impact of the
CRISPR-Cas9 silencing system on ASCT2 and LAT1 expression was initially assessed by
western blot analysis.
In the HUH7 set of CRISPR-Cas9 cell lines, the ASCT2-targeted pC-H7 A3 and the
LAT1-targeted pC-H7 L3 cell lines were the best knockouts of the ASCT2 and LAT1 proteins,
respectively (Fig. 34 B and C). Remarkably, transfection with the A2 CRISPR-Cas9 plasmid
construct lead to a robust knockout of ASCT2 accompanied by the appearance of an unknown,
lower molecular weight band that was reactive with ASCT2 antibody (Fig. 34A, pC-H7 A2).
Glutamine synthetase (GLUL) and cystine-glutamate transporter (xCT) protein expression were
both unaltered by ASCT2 and LAT1 transporter knockout (Fig. 34 D and E, respectively).
Glucose transporter 1 (GLUT1) protein expression was reduced in three of the transfected cell
lines, namely the ASCT2-targeted pC-H7 A3 cell line as well as the LAT1-targeted cell lines,
pC-H7 L1 and L2 (Fig. 34F).
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Figure 34. ASCT2, LAT1, GLUL, xCT and GLUT1 protein expression in CRISPR-Cas9-mediated knockout
HUH7 cell lines. Protein expression was measured by western blot analysis as described in MATERIALS AND
METHODS. (A) The chemiluminescent bands for each target (ASCT2, LAT1, GLUL, xCT and GLUT1) are shown in
comparison to β-actin or COXIV protein detected on the same blots to control for loading error. One image for COXIV is
shown for both xCT and GLUT1 because these proteins were detected on the same blot. (B-E) The band intensity of each
target was quantified using ImageJ analysis software and normalized to β-actin or COXIV band intensity in each lane.
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In the SK Hep set of CRISPR-Cas9 cell lines, the ASCT2-targeted pC-SK A3 and the
LAT1-targeted pC-SK L1 cell lines were the best knockouts of the ASCT2 and LAT1 proteins,
respectively (Fig. 35 B and C). Here again, just like in HUH7, SK Hep cells transfected with the
A2 CRISPR-Cas9 plasmid construct also exhibited an unknown, lower molecular weight band
(Fig. 35A, pC-SK A2). GLUL protein expression was not affected by ASCT2 or LAT1 knockout
(Fig. 35D). However, the expression of xCT transporter protein was slightly enhanced in
ASCT2-targeted pC-SK A1 and A2 cell lines as well as LAT1-targeted pC-SK L1 and L2 cell
lines (Fig. 35E). GLUT1 transporter protein expression only demonstrated variability across the
ASCT2-targeted cell lines. GLUT1 expression was diminished in the pC-SK A1 cell line,
whereas it was enhanced in the pC-SK A2 and A3 cell lines (Fig. 35F). Taken together, these
western blots demonstrate that (1) expression of glutamine synthetase does not change in
response to ASCT2 knockout; (2) GLUT1 expression is enhanced in response to ASCT2
knockout in only SK Hep-derived cell lines; and (3) xCT transporter expression may be
moderately responsive to ASCT2 and LAT1 knockout in SK Hep. Furthermore, ASCT2
knockdown appears to be dependent on gRNA sequence identity and not dependent on cell line
identity, due to a similar pattern of knockdown effects observed in HUH7 and SK Hep cell lines
(Figure 34B versus 35B). On the other hand, overall LAT1 knockdown patterns between cell
lines were different, and there may be some underlying distinguishing characteristic of the LAT1
gene that favors the L3 gRNA sequence in HUH7 and the L1 gRNA sequence in SK Hep.

92

Figure 35. ASCT2, LAT1, GLUL, xCT and GLUT1 protein expression in CRISPR-Cas9-mediated knockout SK Hep
cell lines. Protein expression was measured by western blot analysis as described in MATERIALS AND METHODS. (A)
The chemiluminescent bands for each target (ASCT2, LAT1, GLUL, xCT and GLUT1) are shown in comparison to β-actin
or COXIV protein detected on the same blots to control for loading error. One image for COXIV is shown for both xCT and
GLUT1 because these proteins were detected on the same blot. (B-E) The band intensity of each target was quantified using
ImageJ analysis software and normalized to β-actin or COXIV band intensity in each lane.
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Initial rate transport analysis was performed using tritium-radiolabeled L-glutamine and
L-leucine derivatives to evaluate the impact of ASCT2 and LAT1 transporter knockout on
transporter activity. In the glutamine uptake analysis, a distinction between different systems of
glutamine transport was made by adding two chemical inhibitors to the amino acid uptake mixes:
(1) MeAIB, a system A (SNAT1/SNAT2) inhibitor (in medium grey) and (2) GPNA, system
ASC (ASCT2) inhibitor (in light grey). The best HUH7 ASCT2 knockout, pC-H7 A3,
demonstrated a 75% reduction in Na+-dependent initial rate glutamine uptake, and the best SK
Hep ASCT2 knockout, pC-SK A3, demonstrated 90% reduction (Fig. 36A pC-H7 A3; and 36B
pC-SK A3). Glutamine uptake in pC-H7 A3 was not affected by treatment with MeAIB,
suggesting that the residual 25% glutamine transport rate was not attribuTable to SNAT1/2
glutamine transporters. However, treatment with GPNA reduced the already diminished
glutamine uptake further, resulting in 6% of the total glutamine uptake rate unaccounted for (Fig.
36A; pC-H7 A3). The residual 10% glutamine uptake rate in the pC-SK A3 SK Hep cell line was
significantly affected by both MeAIB and GPNA (Fig. 36B; pC-SK A3). This suggests that
SNAT1/2 may participate in glutamine transport to a greater extent in SK Hep as opposed to
HUH7. Assuming that GPNA does not have off-target inhibitory effects, these findings suggest
that in both the pC-H7 A3 and pC-SK A3 cell lines may still maintain ASCT2 transporter
expression that is functional but at a low enough concentration to be undetecTable by western
blot analysis. Furthermore, despite the anomalous appearance of a low molecular weight band in
the ASCT2 western blot for both pC-H7 A2 and pC-SK A2, the Na+-dependent initial rate uptake
of glutamine in these cell lines is comparable to pC-H7 A3 and pC-SK A3, within their
respective parent cell line subsets (Fig. 36A, pC-H7 A2; and 36B, pC-SK A2).
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Figure 36. Na+-dependent glutamine (L-[3H]Gln) transport in ASCT2-targeted CRISPR-Cas9 HUH7 and SK Hep
cell lines. Transport of 10 μM L-glutamine was measured as described in MATERIALS AND METHODS. Due to the Na+dependence of ASCT2-mediated glutamine uptake, the transport values obtained in the absence of extracellular Na+
(diffusion and Na+-independent uptake) were subtracted from those in the presence of Na+ (total uptake) to yield Na+dependent rates. For each cell line, Na+-dependent glutamine transport was also measured in the presence of two small
molecular inhibitors: 2-methylaminoisobutyric acid (MeAIB), a system A glutamine transport inhibitor, and glutaminylpara-nitroanilide (GPNA), a ASCT2 glutamine transport inhibitor. In the first graph, HUH7-derived ASCT2-targeted cell
lines (pC-H7 A1, A2, and A3) are shown respective to the non-silencing control cell line (pC-H7 NS) and the HUH7 parent
cell line (A), and in the second graph SK Hep-derived ASCT2-targeted cell lines (pC-SK A1, A2, and A3) are shown
respective to the non-silencing control cell line (pC-SK NS) and the SK Hep parent cell line (B). Data are the average of at
least four separate determinations ± SD. Asterisks (*) denote values that are statistically significant with a P value < 0.05.
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In the initial rate leucine uptake analysis, system L-mediated leucine transport (LAT1/2)
was distinguished by adding BCH, a system L inhibitor to the uptake mix (in light grey). In
reference to the preceding LAT1 western blots, the best HUH7 LAT1 knockout, pC-H7 L3,
demonstrated an 85% reduction in initial rate leucine uptake, and the best SK Hep LAT1
knockout, pC-SK L1, demonstrated 80% reduction, compared to their non-silencing control cell
lines (pC-H7 NS and pC-SK NS, respectively) (Fig. 37A pC-H7 L3; and 37B pC-SK L1).
Unexpectedly, the initial rate leucine uptake analysis contradicted the results of earlier LAT1
western blots, and the pC-SK L3 cell line exhibited the best reduction in initial uptake (by 90%),
indicating a better knockdown of LAT1 than the pC-SK L1 cell line (Fig. 37B, pC-SK L1 vs.
pC-SK L3). This result may indicate that LAT1 knockdown is dependent on gRNA sequence
identity, and the L3 CRISPR-Cas9 gRNA sequence is the most effective at targeting LAT1 in
both HUH7 and SK Hep. After CRISPR-Cas9-mediated knockout, the residual initial rate
leucine uptake maintained by the pC-H7 L3, pC-SK L1, and pC-SK L3 cell lines was eliminated
by BCH inhibition, which again, may suggest that these cell lines conserve an expression of
LAT1 at low levels which are still functional but not concentrated enough for a western blot
detect (Fig. 37A and B). Figure 37C is a comparison of initial rate leucine uptake between parent
cell lines and their respective non-silencing cell lines, and there were with no significant
differences amongst these controls. However, in general, this graph shows that the baseline
initial rate leucine uptake is more robust in SK Hep compared to HUH7 cells. Collectively, these
amino acid uptake assays do not show a great degree of compensatory action by other glutamine
and leucine transporters in the ASCT2 and LAT1 knockout cell lines.
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Figure 37. Leucine (L-[3H]Leu) transport in LAT1-targeted CRISPR-Cas9 HUH7 and SK Hep cell lines.
Transport of 10 μM L-leucine was measured as described in MATERIALS AND METHODS. For each cell line,
leucine transport was also measured in the presence of 2-amino-2-norbornanecarboxlic acid (BCH), a system L
leucine transport inhibitor. In the first graph, HUH7-derived LAT1-targeted cell lines (pC-H7 L1, L2, and L3) are
shown respective to the non-silencing control cell line (pC-H7 NS) (A), and in the second graph SK Hep-derived
LAT1-targeted cell lines (pC-SK L1, L2, and L3) are shown respective to the non-silencing control cell line (pC-SK
NS) (B). The third graph is a comparison of leucine uptake between each parent line versus its respective nonsilencing control cell line (C). Data are the average of at least four separate determinations ± SD. Asterisks (*) denote
values that are statistically significant with a P value < 0.05.
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Growth and mTORC1 Signaling

A series of MTT analyses were performed to evaluate changes in proliferative rate in the
transporter knockout cell lines. In the following Figures 38 and 39, non-silencing and parent cell
lines are represented in light grey, and all transporter knockout cell lines and represented in
black. In the HUH7 set, the ASCT2-targeted pC-H7 A1 cell line grew at a moderately slower
rate relative to the non-silencing and parent cell lines (Fig. 38A). Additionally, the two LAT1targeted cell lines that demonstrated the greatest reductions leucine initial rate uptake in the
preceding initial rate leucine uptake analysis, pC-H7 L1 and L3, grew at a slower rate (Fig. 38B).
In the SK Hep set of cell lines, there was no sustained significant difference in proliferative rate
(Fig. 39A and B). These results may demonstrate some statistically significant changes, but
overall the changes in proliferative rate were not substantial and all of these cell lines were
capable of being maintained in long-term cell culture.
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Figure 38. Growth in the ASCT2- and LAT1-targeted CRISPR-Cas9 HUH7 cell lines. Growth was indirectly
measured using an MTT assay as described in MATERIALS AND METHODS. In the first graph, HUH7-derived ASCT2
knockout cell lines (pC-H7 A1, A2, and A3) are shown respective to the non-silencing control cell line (pC-H7 NS) and
the HUH7 parent line (A), and in the second graph, HUH7-derived LAT1 knockout cell lines (pC-H7 L1, L2, and L3) are
shown respective to the non-silencing control cell line (pC-H7 NS) and the HUH7 parent line (B).
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Figure 39. Growth in the ASCT2- and LAT1-targeted CRISPR-Cas9 SK Hep cell lines. Growth was indirectly measured
using an MTT assay as described in MATERIALS AND METHODS. In the first graph, SK Hep-derived ASCT2 knockout
cell lines (pC-SK A1, A2, and A3) are shown respective to the non-silencing control cell line (pC-SK NS) and the SK Hep
parent line (A), and in the second graph, SK Hep-derived LAT1 knockout cell lines (pC-SK L1, L2, and L3) are shown
respective to the non-silencing control cell line (pC-SK NS) and the SK Hep parent line (B).
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In order to characterize the intensity of mTORC1-mediated growth signaling in the
transporter knockout cell lines, western blot analysis was performed to measure the
phosphorylation state 4E-BP1, a direct target of mTORC1 serine threonine kinase activity
(please refer back to Figure 2 in the INTRODUCTION section for more detail on mTORC1
activity). This assessment of mTORC1 activity was implemented under controlled conditions of
growth factor stimulation, amino acid availability, and rapamycin treatment. In Figures 40 and
41, the five vertical lanes for each cell line represent sequential treatment conditions (from left to
right): (1) normal growth medium (+FBS/+AA), (2) growth medium without serum-derived
growth factor stimulation (-FBS/+AA), (3) growth medium without both serum-derived growth
factor and amino acid stimulation (-FBS/-AA), (4) normal growth medium with an ethanol
(EtOH) vehicle control (+FBS/+AA/+EtOH), and (5) normal growth medium with rapamycin
treatment (+FBS/+AA/+20 nM Rapa). Overall, neither the HUH7 nor the SK Hep CRISPR-Cas9
transporter knockout cell lines exhibited any qualitative differences in 4E-BP1 phosphorylation
state relative to their respective non-silencing control cell lines. Simultaneous removal of serumderived growth factors and amino acids provoked the most pronounced suppression of higher
level 4E-BP1 phosphorylation in all of the cell lines.
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Figure 40. The influence of growth factor signaling, amino acid availability, and rapamycin treatment
on 4E-BP1 phosphorylation in ASCT2- and LAT1-targeted CRISPR-Cas9 HUH7 cell lines. The
phosphorylation state of 4E-BP1 was measured by western blot analysis as described in MATERIALS AND
METHODS. In order to control for loading, the chemiluminescent bands exposed for each target (total 4EBP1 and phospho-4E-BP1) are paired to β-actin protein detected on the same blots, respectively. Each array
of western blots is a comparison of 4E-BP1 phosphorylation state changes over time as these cell lines were
sequentially exposed to the stimulatory and inhibitory conditions described in the Table at the bottom of this
Figure. The non-silencing control cell line (pC-H7 NS) is shown in parallel to the ASCT2-targeted HUH7
cell line (pC-H7 A3) (A), the LAT-targeted HUH7 cell line (pC-H7 L3) (B), and the parent HUH7 cell line
(C).
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Figure 41. The influence of growth factor signaling, amino acid availability, and rapamycin treatment on
4E-BP1 phosphorylation in ASCT2- and LAT1-targeted CRISPR-Cas9 SK Hep cell lines. The
phosphorylation state of 4E-BP1 was measured by western blot analysis as described in MATERIALS AND
METHODS. In order to control for loading, the chemiluminescent bands exposed for each target (total 4E-BP1
and phospho-4E-BP1) are paired to β-actin protein detected on the same blots, respectively. Each array of western
blots is a comparison of 4E-BP1 phosphorylation state changes over time as these cell lines were sequentially
exposed to the stimulatory and inhibitory conditions described in the Table at the bottom of this Figure. The nonsilencing control cell line (pC-SK NS) is shown in parallel to the ASCT2-targeted SK Hep cell line (pC-SK A3)
(A), the LAT-targeted SK Hep cell line (pC-SK L1) (B), and the parent SK Hep cell line (C).
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Intracellular Accumulation of Glutamine and Leucine

The results of the following assay had the most profound impact on this study. In order to
determine if decreased glutamine and leucine initial rate uptake had an effect on the intracellular
accumulation of these amino acids, prolonged uptake of tritium-radiolabeled L-glutamine and Lleucine was performed for an incubation time of one hour. It is important to note that, unlike the
earlier initial rate uptake experiments, these amino acid accumulation experiments are performed
in the presence of physiological concentrations of all amino acids, serum-derived growth factors,
glucose, and sodium bicarbonate. Therefore, these measurements are reflective of total glutamine
or leucine uptake without distinction between factors that characterize distinct amino acid
transporters, such as sodium-dependence.
The LAT1-targeted pC-H7 L3 and pC-SK L1 cell lines, derived from HUH7 and SK Hep
respectively, demonstrated small increases to their levels of glutamine accumulation (Fig. 42A,
pC-H7 L3; and 42B, pC-SK L1). The ASCT2-targeted HUH7 cell line, pC-H7 A3, exhibited a
moderately reduced level of glutamine accumulation (Fig. 42A, pC-H7 A3), and the LAT1targeted SK Hep cell line, pC-SK L1, also had a moderate reduction in leucine accumulation
(Fig. 42D, pC-SK L1). Strikingly, the variation between cell lines seen here is starkly different
from the more extensive differences in glutamine and leucine initial rate uptake between these
cell lines. Despite transporter knockout in these cell lines, the cells are still capable of
accumulating the same relative intracellular concentrations of amino acids over time. These
results explain why transporter knockout cell lines do not have greatly altered proliferation or
mTORC1 growth signaling despite substantially decreased rates of glutamine and leucine uptake.
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Figure 42. Intracellular glutamine (L-[3H]Gln) and leucine (L-[3H]Leu) accumulation over 1 hr in ASCT2- and
LAT1-targeted CRISPR-Cas9 HUH7 and SK Hep cell lines. Accumulation of 100 μM L-glutamine and 800 μM Lleucine was measured as described in MATERIALS AND METHODS. Intracellular accumulation of glutamine was
measured in ASCT2- and LAT1-targeted HUH7 cell lines (pC-H7 A3 and L3, respectively) in comparison to the nonsilencing control cell line (pC-H7 NS) and parent HUH7cell line (A), and in ASCT2- and LAT1-targeted SK Hep cell
lines (pC-SK A3 and L1 respectively) in comparison to the non-silencing control cell line (pC-SK NS) and parent SK Hep
cell line (B). Intracellular accumulation of leucine was measured in ASCT2- and LAT1-targeted HUH7 cell lines (pC-H7
A3 and L3, respectively) in comparison to the non-silencing control cell line (pC-H7 NS) and parent HUH7cell line (C),
and in ASCT2- and LAT1-targeted SK Hep cell lines (pC-SK A3 and L1 respectively) in comparison to the non-silencing
control cell line (pC-SK NS) and parent SK Hep cell line (D). Data are the average of at least four separate determinations
± SD. Asterisks (*) denote values that are statistically significant with a P value < 0.05.
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In order to determine how rapidly the CRISPR-Cas9 transporter knockout cell lines are
able to achieve intracellular concentrations of amino acids comparable to controls, uptake of
tritium-radiolabeled L-glutamine and L-leucine was performed for incremental incubation times
over the span of one and a half hours (Figure 43). In the HUH7 set of CRISPR-Cas9 cell lines,
ASCT2-targeted pC-H7 A3 demonstrated significantly reduced intracellular glutamine
accumulation at all time points. However, this difference became less substantial over time, from
a 41% initial difference at 30 seconds to a 21% difference after one and half hours (Fig. 43A,
pC-H7 A3). The pC-H7 A3 cell line also demonstrated a small but significant reduction in
intracellular leucine accumulation (20-26%) at the time points of 30 sec and 1 minute, but this
difference was recovered to non-significant levels by the 10 minute time point (Fig. 43B, pC-H7
A3). The LAT1-targeted pC-H7 L3 cell line demonstrated a large reduction in intracellular
leucine accumulation at the initial time points of 30 seconds and 1 minute (70% and 56%,
respectively), but this difference was reduced to non-significant levels by the 10 minute time
point (Fig. 43B, pC-H7 L3). In the SK Hep set of CRISPR-Cas9 cell lines, both pC-SK A3 and
pC-SK L1 demonstrated significantly changes to intracellular glutamine accumulation.
Compared to the non-silencing control cell line, pC-SK NS, the difference in glutamine
accumulation for the pC-SK A3 cell line was substantially reduced over time, from a 100%
difference to a 21% difference after one and half hours (Fig. 43A, pC-SK A3). Glutamine
accumulation in the pC-SK L1 cell line was more variable, and pC-SK L1 demonstrated an
increased glutamine accumulation at the intial 30 second time point, but after one and half hours,
glutamine accumulation had dropped to 19% of that of the control pC-SK NS cell line (Fig. 43A,
pC-SK L1). These two cell lines, pC-SK A3 and pC-SK L1, also demonstrated significantly
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reduced intracellular leucine accumulation (Fig. 43B, pC-SK A3 and L1). The difference in
leucine accumulation for pC-SK A3 was small (20-30%) across the time points, and by an hour
and a half of incubation time, leucine accumulation by pC-SK A3 recovered to a comparable
level to the control pC-SK NS cell line. The LAT1-targeted pC-SK L1 cell line demonstrated a
more substantial difference in initial intracellular leucine accumulation that gradually recovered
over time, from a 96% difference at 30 seconds to 20% difference after one and half hours.
These results show that CRISPR-Cas9 transporter targeted cell lines are able to maintain
intracellular concentrations of glutamine and leucine that are comparable to controls given
enough time to grow in cell culture, and again, changes in initial rate uptake are not reflective of
intracellular availability in vitro.
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Figure 43. Intracellular glutamine (L-[3H]Gln) and leucine (L-[3H]Leu) accumulation over time. Accumulation of 100
μM L-glutamine and 800 μM L-leucine was measured as described in MATERIALS AND METHODS. Intracellular
accumulation of glutamine (A) and leucine (B) was measured in ASCT2- and LAT1-targeted HUH7 cell lines (pC-H7 A3 and
L3, respectively) in comparison to the non-silencing control cell line (pC-H7 NS), and in ASCT2- and LAT1-targeted SK Hep
cell lines (pC-SK A3 and L1, respectively) in comparison to the non-silencing control cell line (pC-SK NS). Data are the
average of at least four separate determinations ± SD. Asterisks (*) denote values that are statistically significant with a P value
< 0.05.
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In order to determine if transporter knockout led to any changes in the intracellular ratio
of free amino acids versus biosynthetically incorporated amino acids (integral to macromolecules
such as charged tRNA, proteins, and nucleic acids), an acid precipitation was performed with
10% trichloroacetic acid (TCA) and measurements of tritium-radiolabeled L-glutamine and Lleucine were taken for soluble versus insoluble fractions (Figure 44). Overall, the intracellular
ratio of free to incorporated glutamine (labeled in Figure 44 as ‘transport’ and ‘biosynthetic,’
respectively) was not significantly different across any of the CRISPR-Cas9 cell lines, and this
ratio ranged between 70:30% and 75:25% free:incorporated glutamine (Fig. 44A). Similarly, the
intracellular ratio of free to incorporated leucine was also not significantly different within the
HUH7 and SK Hep sets of CRISPR-Cas9 cell lines. However, there was a greater fraction of free
leucine in SK Hep compared to HUH7 by roughly 10% of the total intracellular pool. For the
HUH7 set, the ratio ranged between 31:69% and 33:67% free:incorporated leucine, and for the
SK Hep set, the ratio ranged between 41:59% and 46:59% free:incorporated leucine (Fig. 44B).
Significant differences in the distinct quantities of free or incorporated amino acids in each cell
line were reflective of the significant differences in total accumulation. These results indicate
that transporter knockout of ASCT2 or LAT1 does not affect the percentage of transported amino
acid that will be biosynthetically incorporated over time.
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Figure 44. Free versus incorporated intracellular glutamine (L-[3H]Gln) and leucine (L-[3H]Leu). After 90
minutes of accumulation, intracellular fractions of free and biosynthetically incorporated radioactive L-glutamine
and L-leucine were measured as described in MATERIALS AND METHODS. Intracellular glutamine (A) and
leucine (B) was measured ASCT2- and LAT1-targeted HUH7 cell lines (pC-H7 A3 and L3, respectively) in
comparison to the non-silencing control cell line (pC-H7 NS), and in ASCT2- and LAT1-targeted SK Hep cell lines
(pC-SK A3 and L1, respectively) in comparison to the non-silencing control cell line (pC-SK NS). Data are the
average of at least four separate determinations ± SD. Asterisks (*) denote values that are statistically significant
with a P value < 0.05.
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Initial Rate Arginine Uptake

Initial rate transport analysis was performed using a tritium-radiolabeled L-arginine
derivative to assess the impact of CRISPR-Cas9-mediated transporter knockout on arginine
transport activity. L-arginine is largely mediated by cationic amino acid transporter-1 (CAT1),
and arginine transport and metabolism plays a role in the progression of many cancers (Qiu,
Huang, and Sui, 2015). L-arginine uptake was significantly increased in the ASCT2-targeted pCSK A3 SK Hep cell line, suggesting that ASCT2 knockout may trigger CAT1 transporter activity
(Fig. 45). This assay was originally performed to determine if transporter knockout led to the
import of alternative metabolic substrates. However, if intracellular accumulation of glutamine is
relatively unchanged in pC-SK A3, this relationship is not dependent on glutamine deprivation,
and instead, might be resultant of transporter dynamics more localized to the plasma membrane.
CAT1-mediated uptake of arginine is a sodium-independent mechanism, but it is still
driven by the electrochemical charge distribution across the cell membrane. ASCT2 activity is
sodium-dependent because its amino acid exchange mechanism is driven by the import of
sodium ions into the cell. Therefore, in the absence of ASCT2 activity, the localized import of
sodium ions across the plasma membrane is impacted, and this may result in a steeper
electrochemical gradient across the cell membrane and a stronger force to drive cationic amino
acid import by CAT1.
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Figure 45. Arginine (L-[3H]Arg) transport in ASCT2- and LAT1-targeted CRISPR-Cas9 HUH7 and SK Hep cell
lines. Transport of 10 μM L-arginine was measured as described in MATERIALS AND METHODS. ASCT2- and LAT1targeted HUH 7 cell lines (pC-H7 A3 and L3 respectively) are shown compared to the non-silencing control cell line (pCH7 NS). ASCT2- and LAT1-targeted SK Hep cell lines (pC-SK A3 and L1 respectively) are shown compared to the nonsilencing control cell line (pC-SK NS). Arginine uptake is also shown in comparison between each non-silencing control
cell line and its respective parent cell line (pC-H7 NS vs. HUH7 and pC-SK-NS vs. SK Hep). Arginine transport was
measured in both the presence (Na+) and absence (Chol) of extracellular Na+. Data are the average of at least four separate
determinations ± SD. Asterisks (*) denote values that are statistically significant with a P value < 0.05.
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ASCT2 and LAT1 mRNA Expression after CRISPR-Cas9 Knockout

The CRISPR-Cas9 mechanism of gene silencing does not prevent the transcription of the
edited target genes, but it is possible that transporter knockout cells would respond to the insult
by a futile upregulation in transcription of the defective gene. Furthermore, the altered ASCT2
and LAT1 mRNA transcripts may illicit an increased turnover if they are recognized in some
way by endogenous cellular machinery. To explore the impact of the CRISPR-Cas9 system on
ASCT2 and LAT1 mRNA abundance, RT-qPCR analysis was performed. ASCT2 and LAT1
mRNA expression was similar between the transporter knockout, non-silencing control, and
parent cell lines in the SK Hep CRISPR-Cas9 subset. However, the ASCT2-targeted HUH7 cell
line pC-H7 A3 exhibited a 90% reduction in ASCT2 mRNA (Fig. 46A, pC-H7 A3) as well as a
50% reduction of LAT1 mRNA (Fig. 46B, pC-H7 A3), relative to the non-silencing pC-H7 NS
cell lines. LAT1 mRNA was also diminished by 85% in the LAT1-targeted HUH7 cell line pCH7 L3 (Fig. 46B, pC-H7 L3). The controls for the HUH7 set, the non-silencing and parent
HUH7 cell line, were also different in terms of ASCT2 and LAT1 expression, and this may make
the results of this analysis more subject to doubt.
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Figure 46. ASCT2 and LAT1 mRNA expression in the CRISPR-Cas9-mediated knockout HUH7 and SK Hep
cell lines. ASCT2 and LAT1 mRNA expression was measured by quantitative RT-PCR analysis as described in
MATERIALS AND METHODS. Each target mRNA expression level is represented as a geometric mean of three
experimental RT-qPCR runs relative to the expression level of both TBP and HMBS housekeeping genes (HKG). In
both graphs, ASCT2- and LAT1-targeted HUH7 cell lines (pC-H7 A3 and L3 respectively) are shown in comparison
to the non-silencing control cell line (pC-H7 NS) and parent HUH7cell line, and ASCT2- and LAT1-targeted SK Hep
cell lines (pC-SK A3 and L1 respectively) are shown in comparison to the non-silencing control cell line (pC-SK NS)
and parent SK Hep cell line. The first graph illustrates the relative expression levels of ASCT2 mRNA in each cell line
(A), and the second graph illustrates the relative expression levels of LAT1 mRNA (B).
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Revisiting xCT Transporter Expression

In the preceding shRNA-based investigation, an observation was made after RT-qPCR
analysis that, in SK Hep, cystine-glutamate (xCT) transporter mRNA expression increased
following shRNA-mediated ASCT2 and LAT1 transporter suppression (please see Fig. 24H of
the Growth, mTORC1 Signaling, and Compensatory Expression section of CHAPTER 1). RTqPCR analysis of xCT expression was later performed in CRISPR-Cas9-mediated knockout cell
lines, and a small increase in xCT mRNA expression was exhibited in the ASCT2-targeted SK
Hep cell line, pC-SK A1 (Fig. 47B). However, pC-SK A1 was the only cell line from the
ASCT2-targeted SK Hep set that did not exhibit a reduction in either ASCT2 protein or activity
(Fig. 35B and 36B). Furthermore, western blot analysis of xCT protein expression also revealed
no difference in xCT expression across the shRNA-mediated knockdown and CRISPR-Cas9
knockout sets of SK Hep cell lines (Fig. 47 C and D). So, this early observation about xCT
transporter expression could not be corroborated.
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Figure 47. xCT mRNA expression in the shRNA-mediated knockdown versus CRISPR-Cas9-mediated knockout SK
Hep cell lines. Cystine-glutamate antiporter (xCT) mRNA expression was measured by quantitative RT-PCR analysis (A and
B), and xCT protein expression was measured by western blot analysis (C and D), both as described in MATERIALS AND
METHODS. xCT mRNA expression level is represented as a geometric mean of three experimental RT-qPCR runs relative
to the expression level of both TBP and HMBS housekeeping genes (HKG). In order to control for loading in the western
blot analysis, the chemiluminescent bands exposed for xCT protein are paired to β-actin protein detected on the same blots,
respectively. For the shRNA-mediated knockdown cell lines (A and C), the ASCT2- and LAT1-targeted SK Hep cell lines
(SA2, SA5, SL1 and SL2 respectively) are shown in comparison to the non-silencing control cell line (SNS) and parent SK
Hep cell line. For the CRISPR-Cas9-mediated knockout cell lines (B and D), the ASCT2-targeted SK Hep cell lines (pC-SK
A1, A2, and A3) are shown in comparison to the non-silencing control cell line (pC-SK NS).
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Revisiting Antisense RNA-mediated ASCT2 Suppression

A recurrent problem in this study has been the incomplete silencing of ASCT2 and
LAT1. Even when western blots fail to detect target transporter protein in shRNA- and CRISPRCas9-targeted cell lines, radiolabeled amino acid uptake assays have revealed residual ASCT2
and LAT1 activity.
In order to refine the level of ASCT2 suppression that was responsible for eliciting cell
death in the early ASCT2-targeted antisense RNA study, the SK Hep-derived antisense (AS1-1)
and sense (S2-1) cells, two cell lines previously established by Fuchs and Bode, 2004, were
revisited (please refer back to Former Ventures in Targeting ASCT2 in CHAPTER 1 for more
detail on the mechanism of silencing using this system). After AS1-1 and S2-1 cells were treated
with a mifepristone (MFP) inducing agent in serial dilution, ASCT2 protein expression was
measured by western blot analysis (Fig. 48A) and cell growth was measured by MTT assay (Fig.
48B). The minimum concentration of MFP that resulted in cell death was 0.1 nM. Importantly, at
the time of cell death (48 hr) and at a standard dosage of MFP (10 nM), ASCT2 protein is still
detecTable by western blot analysis (Fig. 48A, ASCT2 48 hr). These results indicate that the cell
death that occurred after ASCT2 knockdown in the antisense RNA system did not require a
complete elimination of the ASCT2 transporter protein.
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Figure 48. The effect of serial dilution treatments of mifepristone (MFP) on ASCT2 protein expression and
growth in AS1-1 and S2-1 SK Hep-derived cell lines. AS1-1 and S2-1 are MFP-inducible antisense cell lines
established by Dr. Brian Fuchs and Dr. Barrie Bode as an early system of studying ASCT2 knockdown in SK Hep
(Fuchs, Perez, Suetterlin, Chaudhry, & Bode, 2004). In that work, the experimental antisense AS1-1 cell line was
demonstrated to have a rapid decline in ASCT2 post induction that was correlated with well-characterized apoptosis. The
sense S2-1cell line was used as a system control in which no antisense RNA is generated. Herein, these two cell lines
were treated with a range of MFP concentrations (10 pM – 10 nM), and protein expression and growth over time was
measured by western blot and MTT analysis respectively, both as described in MATERIALS AND METHODS. The
chemiluminescent bands for ASCT2 for each time point are shown in comparison to β-actin protein detected on the same
blots to control for loading error (A). AS1-1 (grey) is shown respective to S2-1 (black)(B).
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Discussion

HUH7 and SK Hep HCC cell lines that were successfully transfected with the pCLIPAll-EFS-Puro-CRISPR-Cas9 plasmid vectors were obtained by puromycin selection. CRISPRCas9-mediated knockout of the ASCT2 and LAT1 genes (SLC1A5 and SLC7A5, respectively)
was demonstrated by western blot and initial rate uptake analysis. The unique A3 and L3 gRNA
sequence designs were determined to be the most effective at targeting the SLC1A5 and SLC7A5
genes respectively, in both cell lines.
The two best ASCT2 knockout cell lines, pC-H7 A3 and pC-SK A3, demonstrated
reductions in initial rate glutamine uptake by 75% and 90%, respectively, and the two best LAT1
knockout cell lines, pC-H7 L3 and pC-SK L3, demonstrated reductions in initial rate leucine
uptake by 85% and 90%, respectively. In the ASCT2 knockout cell lines, the remaining initial
rate glutamine uptake was effectively suppressed with the system-ASC specific inhibitor GPNA,
suggesting that, despite being undetecTable by western blot analysis, some remaining ASCT2
expression was retained after CRISPR-Cas9 gene editing. Likewise, in the LAT1 knockout cell
lines, the remaining initial rate leucine uptake was effectively suppressed with the system-L
specific inhibitor BCH, and again, this indicates that a small amount of LAT1 expression may
have also been retained. One potential way that this can occur is if the CRISPR-Cas9 gene
editing system isn’t absolutely efficient and the Cas9 endonuclease occasionally creates
heterozygous gene edits. Recall from Chapter 1 that variable tGFP expression was visible within
each population of transfected cells, and this was potentially indicative of variable transcription
of the genomically integrated transgenic DNA between individual cells. Similarly, the
transfected population of cells resulting from CRISPR-Cas9 knockout might be a mixture of
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cells with heterozygous and homozygous gene edits. The greater extent of ASCT2 and LAT1
knockout in SK Hep, as compared to HUH7, may be evidence that homozygous gene edits were
more prevalent in SK Hep and represented a greater percentage of the resultant populations.
A few cell lines derived from HUH7, pC-H7 A1, L1, and L3, exhibited a slower
proliferative rate than their non-silencing and parent cell line controls. However, no change in
proliferative rate was evident in any of the transporter knockout cell lines derived from SK Hep.
Additionally, 4E-BP1 phosphorylation specific western blot analyses confirmed that mTORC1mediated growth signaling was not altered across any of the transporter knockout cell lines.
Similar to the results of the shRNA-targeting system, western blot analysis showed that
glutamine synthetase (GLUL) expression did not change in response to ASCT2 or LAT1
knockout. Glucose transporter 1 (GLUT1) expression was variable, and HUH7-derived cell lines
pC-H7 A3, L1, and L2 exhibited reductions in GLUT1 protein, whereas, SK Hep-derived cell
lines, pC-SK A2 and A3 exhibited increased expression of GLUT1 protein. Upon revisiting the
early observation that cystine-glutamate (xCT) transporter mRNA expression increased
following shRNA-mediated ASCT2 and LAT1 transporter suppression in SK Hep, the results
could not be validated using CRISPR-Cas9-mediated knockout of ASCT2 and LAT1 in SK Hep.
In perhaps one of the most important assays in this study, the prolonged uptake of
tritium-radiolabeled L-glutamine and L-leucine revealed that ASCT2 and LAT1 knockouts cells
are still capable of accumulating the same relative intracellular concentrations of amino acids as
the non-silencing and parent cell lines over time. Furthermore, ASCT2 and LAT1 transporter
knockout does not affect the percentage of transported amino acids that will be biosynthetically
incorporated over time. The enduring intracellular amino acid accumulation and availability

120

within transporter knockout cell lines is a supportive of the early measurements that revealed
unsubstantial changes in proliferative rates and mTORC1 growth signaling.
Initial rate arginine uptake analysis revealed an increase in arginine uptake in response to
ASCT2 knockout in SK Hep cells. Given the results of the preceding amino acid accumulation
experiments, this response is not mediated by an intracellular depletion of glutamine. Cationic
amino acid transporter 1 (CAT1) is principally responsible for arginine uptake in a sodiumindependent mechanism (Qiu et al., 2015). Though, as previously suggested, it’s possible that in
absence of ASCT2 activity, there is a decrease in the net influx of sodium ions into the cell, and
this could result in a steeper electrochemical gradient across the cell membrane and a stronger
electrochemical force to drive cationic amino acid import by CAT1.
In the forerunner work to this study, the antisense RNA system suggested that ASCT2
knockdown elicits an apoptotic response in SK Hep (Fuchs et al., 2004). The current study
attained levels of ASCT2 suppression in HUH7 and SK Hep that surpass the reduced ASCT2
expression achieved in that early study and determined to be necessary to stimulate apoptosis.
Therefore, the cause of death in that study may have not been ASCT2 knockout. The antisense
transcript used in that work was large, roughly ~1.3 kb in length, with an 82% complementarity
to the endogenous ASCT2 mRNA transcript. It is possible that, once the antisense transcript
formed a double-stranded complex with the endogenous ASCT2 mRNA transcript and was
subsequently cleaved by DICER processing, the resulting array of small microRNA (miRNA)
duplexes could allow the RNA-induced silencing complex (RISC) to destructively target more
than just the endogenous ASCT2 mRNA transcript. These alternative miRNA off-target effects
may be to blame for cell death, and this question might be answered though a comparison
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between the ASCT2 mRNA and other endogenous mRNA transcripts for sequence homology.
The results of this study are a direct contradiction of those early findings, and therefore, the
ASCT2 and LAT1 transporters may not have as critical of a role in cell survival in vitro than
previously thought.
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CHAPTER 3: INTERPRETATION AND THE FUTURE OF TARGETING ASCT2 AND LAT1

The results presented in this study indicate that sTable targeting of ASCT2 and LAT1
with shRNA and CRISPR-Cas9 modalities is met with substantial resistance in HCC cell lines.
Cells that emerge under selective pressure exhibit significant transporter reductions, but are
otherwise able to adapt with minimal changes to growth rate and mTORC1 activity. These
results underscore the inherently plastic adaptations of human HCC, which are likely to manifest
in vivo secondary to transporter targeting in therapeutic applications.
ASCT2 has been shown to be functionally important to growth and tumorigenicity in
several types of cancer including liver, breast, skin, lung, prostate, and myeloid cancers (Fuchs et
al., 2004; Hassanein et al., 2013; van Geldermalsen et al., 2015; Q. Wang et al., 2014; Q. Wang
et al., 2015; Willems et al., 2013). Likewise, LAT1 has also been shown to play a pivotal role in
a similarly broad spectrum of cancers (Q. Wang and Holst, 2015). This study has shown that
epithelial (Hep 3B and HUH7) and mesenchymal (SK Hep) HCC cell lines are able to survive
with stably reduced ASCT2 and LAT1 expression without substantial compromise to
proliferative rates or inherent mTORC1 signaling in vitro. The shRNA-mediated knockdown and
CRISPR-Cas9-mediated knockout of ASCT2 and LAT1 transporters was severely detrimental to
the rate of amino acid uptake, but intracellular glutamine and leucine accumulation from the
extracellular space was not impeded. When conditions are ideal and extracellular resources are
abundant, ASCT2 and LAT1 transporter knockdown may have little influence on survival, but
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the upregulation of these transporters in cancer maybe advantageous to more competitive
conditions, such as the nutrient and oxygen poor tumor microenvironment. In cell culture, each
cell line and its derivative transfectants are grown in monoculture, without the selective pressures
of intercellular competition. The results of this study do not rule out the possibility that other
cellular functions may be compromised within the ASCT2 and LAT1 transporter suppressed
HCC cell lines, and further in vivo analysis will be necessary to evaluate any changes in their
tumorigenic potential and metastatic competence after sTable ASCT2 and LAT1 transporter
knockout.
For both the shRNA and CRISPR-Cas9 silencing modalities, a greater degree of ASCT2
and LAT1 suppression was achieved using the SK Hep cell line relative to the Hep 3B and
HUH7 cell lines, and this might suggest that the expression of ASCT2 and LAT1 is more critical
to epithelial-type HCC survival than mesenchymal-type HCC. Alternatively, the Hep 3B and
HUH7 cell lines may not be as capable of dynamic adaptive responses to considerable changes to
their nutrient uptake and metabolic programming. SK Hep cells may have a greater adaptive
ability, but the underlying mechanism by which all three of these cell lines were able to maintain
an ideal intracellular concentration of glutamine and leucine is still unknown.
Ultimately, this study has shown that ASCT2 and LAT1 are not viable therapeutic targets
by themselves. HCC cells have the capacity to adapt to ASCT2 and LAT1 loss of function. There
is still a potential that these transporters support tumorigenic or metastatic capacities in vivo, and
ASCT2 and LAT1 may still be exceptional targets in prognostic applications in HCC due to their
discriminating expression in cancerous tissue.
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